Increased chromatin accessibility mediated by nuclear factor I drives transition to androgen receptor splice variant dependence in castration-resistant prostate cancer

Larysa Poluben[1,*], Mannan Nouri[1,*], Jiaqian Liang[1], Andreas Varkaris[1], Betul Ersoy-Fazlioglu[1], Olga Voznesensky[1], Irene I. Lee[2,3], Xintao Qiu[2,3], Laura Cato[2], Ji-Heui Seo[2], Matthew L. Freedman[2,3,4], Adam G. Sowalsky[5], Nathan A. Lack[6,7,8], Eva Corey[9], Peter S. Nelson[10,11,12], Myles Brown[2,3], Henry W. Long[2,3], Joshua W. Russo[1], Steven P. Balk[1]

[1]Department of Medicine and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
[2]Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
[3]Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
[4]Eli and Edythe L. Broad Institute, Cambridge, MA, USA
[5]Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, MD, USA
[6]Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, V6H 3Z6 Canada.
[7]Department of Medical Pharmacology, School of Medicine, Koç University, Istanbul, 34450, Turkey.
[8]Koç University Research Centre for Translational Medicine (KUTTAM), Koç University, 34450, Istanbul, Turkey.
[9]Department of Urology, University of Washington School of Medicine, Seattle, Washington, USA
[10]Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington, USA
[11]Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
[12]Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA

*co-first authors

Address correspondence to Steven P. Balk, Tel: 1-617-735-2065; Fax: 1-617-735-2060; Email: sbalk@bidmc.harvard.edu; or Joshua W. Russo, Tel: 1-617-735-2111; Fax: 1-617-735-2065; Email: jrusso1@bidmc.harvard.edu

ABSTRACT

Androgen receptor (AR) splice variants, of which ARv7 is the most common, are increased in prostate cancer (PC) that develops resistance to androgen signaling inhibitor drugs, but the extent to which these variants drive AR activity, and whether they have novel functions or dependencies, remain to be determined. We generated a subline of VCaP PC cells (VCaP16) that is resistant to the AR inhibitor enzalutamide (ENZ) and found that AR activity was independent of the full-length AR (ARfl), despite its continued high-level expression, and was instead driven by ARv7. The ARv7 cistrome and transcriptome in VCaP16 cells mirrored that of the ARfl in VCaP cells, although ARv7 chromatin binding was weaker, and strong ARv7 binding sites correlated with higher affinity ARfl binding sites across multiple models and clinical samples. Notably, although ARv7 expression in VCaP cells increased rapidly in response to ENZ, there was a long lag before it gained chromatin binding and transcriptional activity. This lag was associated with an increase in chromatin accessibility, with the AR and nuclear factor I (NFI) motifs being most enriched at these more accessible sites. Moreover, the transcriptional effects of combined NFIB and NFIX knockdown versus ARv7 knockdown were highly correlated. These findings indicate that ARv7 can drive the AR program, but that its activity is dependent on adaptations that increase chromatin accessibility to enhance its intrinsically weak chromatin binding.

INTRODUCTION

Prostate cancer (PC) that recurs after standard androgen deprivation therapy (ADT) with a GnRH agonist or antagonist (castration-resistant prostate cancer, CRPC) is in most cases still dependent on androgen receptor (AR) activity driven by residual androgens [1-3]. AR activity in CRPC tumors can be further suppressed by agents such as abiraterone, which decreases adrenal androgen synthesis, or use of more effective AR antagonists, such as enzalutamide (ENZ), apalutamide, and darolutamide [4-6]. Unfortunately, patients treated with these androgen-signaling inhibitor (ASI) drugs invariably progress. Therapeutic options for these patients are then taxanes, or PARP inhibitors in men with *BRCA2* loss, but responses to these agents are not durable. A subset of tumors that progress despite ADT combined with ASI drugs become AR independent, with loss of AR expression in some cases, or reduced AR expression and loss of AR transcriptional activity in other cases [7]. A subset of these AR-independent tumors express neuroendocrine markers and have undergone varying degrees of neuroendocrine differentiation, and is referred to as neuroendocrine PC [8]. Others that are AR negative and do not express neuroendocrine markers have been termed double-negative PC [7]. However, the majority of tumors that become resistant to ADT and ASI drugs continue to express high levels of AR and exhibit AR transcriptional activity.

The high levels of AR expression in CRPC are in part driven by amplification of the *AR* gene and an upstream enhancer, which occurs in the majority of cases [9-11], and can enhance responses to low levels of androgen. A smaller subset of these tumors has mutations in the AR-ligand binding domain (LBD) that allow alternative steroids or antagonists to act as agonists which may compromise the efficacy of available ASIs [12-14]. Moreover,

one particular mutation in the LBD allows ENZ to act as an agonist, although this is rarely found in clinical samples [15, 16]. Multiple studies also suggest that activation of several signaling pathways may directly or indirectly enhance AR activity at low androgen levels or in the presence of antagonists [17]. Finally, increasing evidence indicates that expression of AR-splice variants that are constitutively active due to a lack of the LBD, of which AR variant-7 (ARv7) is the most common, contributes to persistent AR activity in tumors that progress on ASI therapy [18-23].

ARv7 is generated by splicing to a cryptic exon downstream of exon 3 (encoding the DNA binding domain), resulting in an AR that is truncated after the DNA binding domain. ARv7 expression is low or undetectable in primary PC prior to ADT, but is expressed in most cases of CRPC and is generally further increased in tumors that become resistant to ASI drugs [21, 22]. ARv7 can drive AR activity in cells where ARfl activity is suppressed [24-27]. Moreover, expression of ARv7 in circulating tumor cells in men with CRPC is associated with resistance to treatment with ASI drugs, suggesting it is a mediator of resistance [19, 23, 28]. However, most tumors expressing ARv7 also express high levels of ARfl, so the extent to which ARv7 is an ARfl-independent driver of AR activity or a biomarker of tumors that are more aggressive and resistant due to other mechanisms, including high levels of ARfl, remains unclear. To address the role and biological importance of ARv7 we have generated and characterized an ENZ-resistant subline of VCaP PC cells that expresses both high levels of ARfl and increased levels of ARv7. We find that ARv7 is the major driver of AR activity and is independent of ARfl, but that it is dependent on adaptations that enhance chromatin accessibility for its activity.

RESULTS

ENZ-resistance in VCaP cells is associated with AR reactivation and expression of ARv7

VCaP cells were cultured in medium with increasing concentrations of ENZ (up to 16 μM) over ~2 months to select for ENZ resistance, alongside passage matched vehicle controls. Parental VCaP cells (grown in medium with 10% FBS) with VCaP cells exposed short term (4 days) to 16 μM ENZ (added to medium with 10% FBS) and to the VCaP cells adapted to 16 μM ENZ (VCaP16) were then compared. Addition of ENZ initially suppressed VCaP cell proliferation, but the proliferative rate of the ENZ-adapted VCaP16 cells (maintained on 16 μM ENZ) was comparable to that of the parental VCaP cells (**Figure 1A**). As expected, short-term ENZ treatment of VCaP cells (VCaP-E) initially suppressed the expression of several AR-regulated genes (*KLK3*, *KLK2*, *FKBP5*, and *NKX3.1*) (**Figure 1B**). However, expression of these genes was then partially restored or increased in the VCaP16 cells.

For a more comprehensive assessment we carried out RNA-seq on acutely ENZ-treated VCaP and VCaP16 and compared them to parental VCaP. Consistent with the above results, VCaP cells acutely exposed to ENZ for 4 days had marked decreases in Hallmark gene sets related to Androgen Response (NES -2.4) (**Figure 1C,** left**)** and to proliferation, including G2M Checkpoint (NES -3.54) and E2F Targets (NES -2.90) (not shown), when

103 compared to parental VCaP (**Figure S1A, B**). Interestingly, the MTORC1 gene set was also markedly decreased
104 (NES -3.02) following acute ENZ treatment, consistent with previous data showing that androgen stimulates this
105 pathway [29]. Notably, no Hallmark gene sets were significantly increased in the acutely ENZ treated cells.
106
107 Gene sets related to proliferation and MTORC1 were also decreased in VCaP16 relative to parental VCaP, but
108 to a lesser degree (NES -2.16 for G2M Checkpoint) than in acutely ENZ-treated VCaP cells (**Figure S1A, C**).
109 Moreover, unlike VCaP cells treated initially with ENZ, VCaP16 exhibited no significant changes in the Androgen
110 Response gene set compared to VCaP cells, indicating that AR activity was substantially restored (**Figure 1C,**
111 **right**). This restoration was not associated with a substantial increase in expression of ARfl protein or mRNA
112 (**Figure 1D, E**). Moreover, DNA sequencing did not show the AR LBD mutation reported to enhance ENZ agonist
113 activity or other AR exonic mutations [15, 16] (**Figure S1D**). In contrast, the restored AR-signaling activity in VCaP16
114 was associated with an increase in the ARv7 protein and mRNA, as well as a substantial increase in PSA/KLK3
115 mRNA and protein expression (**Figure 1B, D, E**). Overall, these findings show that AR activity in the VCaP16
116 cells was substantially restored, and this was associated with an increase in ARv7.
117
118 **AR activity in VCaP16 cells is driven by ARv7**
119 We next used siRNA to determine the contribution of ARfl versus ARv7 to the AR activity in the VCaP16 cells.
120 Remarkably, depletion of ARfl with an siRNA against exon 7 (siEx7) had no clear effect on the AR regulated
121 *KLK3* gene (**Figure 2A**). In contrast, selective depletion of ARv7 (siV7) markedly decreased *KLK3* expression,
122 which was also decreased by an siRNA in exon 1 targeting both ARfl and ARv7 (siEx1). We then carried out
123 RNA-seq to compare gene expression in VCaP16 cells treated with control versus ARv7 siRNA, which confirmed
124 that the ARv7 siRNA markedly decreased expression of Hallmark Androgen Response genes (**Figure 2B, S1A**).
125 Conversely, RNA-seq also confirmed that selective downregulation of ARfl with the siEx7 did not significantly
126 decrease expression of genes in this gene set (**Figure 2C, S1A**). Notably, principal component analysis similarly
127 showed that the ARfl knockdown with siEx7 had minimal effect on overall gene expression, while the ARv7 and
128 Ex1 siRNA samples were separated from the control siRNA and clustered together (**Figure 2D**).
129
130 To further assess the contribution of ARfl to AR activity, we treated the VCaP16 cells with an AR degrader (AR
131 PROTAC®, ARCC-32, ARD) targeted to the LBD to selectively decrease ARfl protein (**Figure 2E**). For this
132 experiment we used a relatively high concentration of ARCC-32 (500 nM) to effectively compete with ENZ, which
133 was kept in the medium to avoid transient stimulation of ARfl by androgen in the FBS medium. Notably, the AR
134 degrader decreased expression of PSA, possibly reflecting more potent suppression of ARfl than obtained with
135 the siEx7 siRNA. Despite the decrease in PSA protein, RNA-seq showed that overall AR activity was not
136 decreased by the AR degrader, with a trend toward increased activity **(Figure 2F**). Principal component analysis
137 similarly showed that the AR degrader had minimal overall impact on gene expression as compared to the vehicle
138 (DMSO) control (**Figure 2D**).

139

140 To assess the extent to which ARv7 activity in VCaP16 is reflective of clinical samples, we examined a panel of
141 genes whose expression was correlated with ARv7 protein expression in clinical CRPC [21]. Notably, expression
142 of this gene set was increased in VCaP16 compared to VCaP, and was decreased by siRNA targeting ARv7,
143 consistent with ARv7 functioning similarly in VCaP16 and in CRPC (**Figure 2G**). Finally, we assessed the effects
144 of depleting ARfl versus ARv7 on proliferation. Growth of VCaP16 cells was suppressed by the AR degrader
145 targeting ARfl, but it was more markedly suppressed by ARv7 siRNA (**Figure 2H).** Consistent with this ARv7
146 dependence, Gene Set Enrichment Analysis (GSEA) showed that siARv7-treated VCaP16 cells had marked
147 decreases in E2F targets, G2M Checkpoint, and MTORC1 signaling gene sets, in addition to the decrease in
148 the Androgen Response gene set (see **Figure S1A**). In contrast, these gene sets were not decreased in the
149 siEx7 or AR-degrader treated cells. Together these findings indicated that AR activity in the ENZ-adapted
150 VCaP16 cells was being driven primarily by ARv7.

151

152 **ARv7 has limited chromatin binding capacity acutely following ENZ treatment**

153 We reported previously that ARv7 increases rapidly in response to AR inhibition (in absolute levels and relative
154 to ARfl) [30]. Consistent with our previous report, ARv7 was increased in VCaP cells within 2 days of ENZ
155 treatment, and levels peaked by 7-14 days (**Figure 3A**). However, this increase in ARv7 alone was not sufficient
156 to drive AR-transcriptional activity, as it took several more weeks in culture before the cells became ENZ-resistant
157 with restoration of AR activity. As noted above, this did not reflect selection for cells with ENZ-responsive AR
158 mutations. To determine more broadly whether this reflected selection for a subclone we compared VCaP versus
159 VCaP16 cells by whole exome sequencing (WES), which showed no significant differences in copy number or
160 driving mutations (**Figure S2**).

161

162 To determine whether the lack of initial transcriptional activity was due to failure of ARv7 accumulation in the
163 nucleus, we used immunofluorescence (IF) to examine ARv7 localization. ARv7 was nuclear in both the short-
164 term ENZ-treated cells and in the VCaP16 cells, indicating ARv7 lack of activity was not due to exclusion from
165 the nucleus (**Figure S3A**). Interestingly, ARfl was also primarily nuclear in both the short-term ENZ-treated VCaP
166 (VCaP-E) and VCaP16 cells (**Figure S3B**). To further delineate ARv7 nuclear localization we performed
167 additional co-immunofluorescence of ARv7 and CBP, followed by confocal microscopy. ARv7 was localized
168 primarily in discrete puncta both at 4 days following ENZ treatment and in the VCaP16 cells (**Figure 3B**). There
169 was substantial colocalization of CBP in these structures, consistent with them being transcriptional
170 condensates. Although the number of puncta per cell was greater in the VCaP16 cells (**Figure 3C**), a similar
171 fraction was colocalized with CBP in the VCaP16 cells versus the VCaP-E cells (**Figure 3D**).

172

173 These observations indicated that ARv7 expressed acutely following ENZ treatment partitions into discrete
174 structures consistent with condensates, and that its initial lack of transcriptional activity reflects a defect at a

175 subsequent step. Therefore, we next assessed ARv7 chromatin binding by immunoblotting and ChIP-seq in
176 VCaP cells following 3 days in ENZ (VCaP-E) versus in VCaP16 cells. Notably, ARv7 protein levels were
177 comparable after formaldehyde crosslinking in the chromatin fraction of VCaP-E and VCaP16 cells **(Figure 3E**).
178 In contrast, ChIP-seq showed that ARv7 chromatin binding at specific sites was low in VCaP-E cells, and was
179 substantially increased in the VCaP16 cells (2150 common sites in replicate samples) (**Figure 3F**). ARfl binding
180 was also greater in the VCaP16 cells versus the VCaP-E cells, although the fold increase was less than that for
181 ARv7 (**Figure 3G**). Notably, the number of identified ARfl sites in the VCaP16 cells (52,536 sites) was much
182 greater than the number of ARv7 sites, which may reflect more binding and/or relative efficiency of the available
183 ChIP antibodies (see below). Finally, acute DHT treatment (4 hours) caused an increase in ARfl binding (as
184 expected), but also increased ARv7 binding in the VCaP16 cells, which may reflect mechanisms including
185 ARfl/ARv7 heterodimer formation (see below). Together these data show that the adaptation to ENZ is
186 associated with an increase in the ability of ARv7 to bind specific sites on chromatin.
187
188 **ARv7 binds chromatin independently of ARfl**
189 The persistent AR activity in VCaP16 cells after depletion of ARfl indicated that ARv7 can transactivate
190 independently of ARfl. Consistent with this hypothesis, degradation of ARfl using ARCC-32 did not impair ARv7
191 chromatin binding in VCaP16 cells (**Figure 4A**). We further examined the ARCC-32-treated VCaP16 cells by
192 ChIP-seq. While there was a modest decrease in ARv7 peak intensities at shared sites in response to the ARCC-
193 32 (**Figure 4B**), the number of sites was not decreased, with a trend towards an increased number of ARv7
194 binding sites in the ARCC-32-treated cells (**Figure 4C**). Moreover, the majority of the 3,480 ARv7 sites found in
195 the control VCaP16 cells were also present in the ARCC-32-treated cells (2,682, 77%) (**Figure 4D**).
196
197 We next used the AR degrader ARCC-32 to determine whether ARv7 complexes on chromatin are dependent
198 on ARfl. For these studies cells were initially treated with ARCC-32, and protein complexes on chromatin were
199 then stabilized by double fixation with the cleavable cross-linker DSP and formaldehyde. This was followed by
200 chromatin isolation and solubilization by DNA digestion with benzonase. ARCC-32 again did not diminish the
201 amount of ARv7 associated with chromatin (**Figure 4E**). Immunoprecipitation with an ARv7 specific antibody
202 showed that the trace levels of ARfl that were lost in the ARCC-32-treated cells which could reflect heterodimers
203 or possibly adjacent homodimers on DNA. Notably, ARCC-32 did not decrease the amount of HOXB13 or BRG1
204 that co-precipitated with ARv7, indicating these interactions were not dependent on ARfl. Finally,
205 immunoprecipitation with a HOXB13 antibody further demonstrated that the ARv7 interaction with HOXB13 was
206 independent of ARfl. These findings in VCaP16 cells are consistent with results we recently reported in LNCaP95
207 and CWR22Rv1 cells, where we similarly found that ARv7 was binding to chromatin independently of ARfl [31].
208
209 While these data indicate that ARv7 does not act predominantly as a heterodimer with ARfl in VCaP16 cells,
210 studies with ectopically expressed ARv7 clearly show it can act both as a homodimer and heterodimerize with

211 ARfl [32-35]. A previous study in LNCaP95 cells (LNCaP cells adapted to androgen depleted medium) also found
212 that DHT stimulation increased ARv7 chromatin binding, suggesting ARv7 heterodimerization with ARfl [27]. This
213 DHT-stimulated increase in ARv7 binding was similarly observed in the VCaP16 cells (see Figure 2F). The
214 gained ARv7 binding sites in the VCaP16 cells overlapped with ARfl sites, consistent with ARfl/ARv7
215 heterodimerization (**Figure 4F**). Notably, a heat map of the ChIP-seq data indicates that DHT broadly and
216 proportionately enhances ARv7 binding to sites that are bound more weakly prior to DHT (**Figure 4G**).
217
218 In addition to dimerization, another mechanism by which ARfl may enhance ARv7 binding is through assisted
219 chromatin loading, wherein binding of an ARfl homodimer to a site makes the site more available for subsequent
220 binding by ARv7. Indeed, a previous study found that glucocorticoid receptor (GR) binding at a glucocorticoid
221 responsive element enhances binding of a variant GR to the same site [36]. To test whether ARv7 binding might
222 be enhanced by binding of a steroid receptor at the same sight, we took advantage of the overlap between GR
223 and ARv7 binding sites and asked whether GR activation would enhance ARv7 binding at these sites. LNCaP95
224 cells were treated with vehicle, DHT, or dexamethasone (DEX, GR specific agonist), followed by ARv7 ChIP-
225 seq. We then examined ARv7 binding to the *FKBP5* gene, which is both AR and GR regulated. Consistent with
226 assisted loading, DEX enhanced ARv7 binding at multiple sites in this gene (**Figure S4A**). Similarly, ARv7
227 binding was increased by DEX in the AR/GR (and mineralocorticoid receptor, MR) regulated *SCNN1A* gene. We
228 then examined two previous GR ChIP-seq data sets to identify GR/ARv7 shared sites, and found that DEX
229 caused a broad increase in ARv7 binding to these sites (**Figure S4B, C**). This broad increase was also observed
230 when we examined all ARv7 sites (**Figure 4H**). Together these findings indicate that ARv7 functions
231 independently of ARfl in the VCaP16 cells, but in the presence of androgen can function cooperatively with ARfl
232 through heterodimerization, assisted loading, or possibly other mechanisms. The results also suggest that GR,
233 in addition to directly activating a subset of AR-target genes [37], may indirectly enhance ARfl and/or ARv7 activity
234 by assisted loading. Notably, GR mRNA was not increased in VCaP16 versus VCaP-E cells, while there was a
235 modest increase in MR expression (~31% increase).
236
237 **ARv7 cistrome is enriched for higher affinity ARfl binding sites**
238 Previous studies have been inconsistent as to whether ARv7 has a cistrome and/or transcriptome that is distinct
239 from ARfl [26, 38-42]. In LNCaP95 cells it was found previously that essentially all ARv7 binding sites were also ARfl
240 sites [27]. Similarly, ARv7 ChIP-seq in VCaP16 cells revealed consistent ~2150 peaks, virtually all of which (97%)
241 overlapped with ARfl peaks (**Figure 5A, B**). Notably, while the number of called ARv7 peaks is low relative to
242 ARfl peaks, inspection of the heat maps centered on total ARfl sites indicates that there is a correlation between
243 ARfl and ARv7 binding across most or all ARfl peaks **(Figure 5C**). It is not clear whether the lower number of
244 called ARv7 peaks reflects weaker ARv7 binding to chromatin or lower efficiency of the ARv7 antibody used for
245 ChIP (or both). In support of the former hypothesis, profile plots clearly show that ARfl binding is markedly greater
246 at called ARv7 sites, suggesting these are being picked up by the ARv7 antibody as they reflect higher affinity

247 sites for ARv7 as well as for ARfl (**Figure 5D**). Notably, ARfl binding is also greater in the VCaP16 cells relative
248 to the VCaP-E cells, suggesting that adaptations in the VCaP16 cells that increased ARv7 binding may also
249 increase binding of ENZ-liganded ARfl (**Figure 5E**). As expected, DHT increased ARfl binding in both VCaP and
250 VCaP16 cells.
251
252 To further assess the relationship between ARv7 versus ARfl binding in VCaP16 cells, we plotted normalized
253 read counts for ARv7 versus for ARfl at ARfl unique sites (sites where ARv7 was not called by the HOMER
254 algorithm) and at ARv7 sites (which are all shared with ARfl) (**Figure 5F**). Significantly, ARv7 binding was highly
255 correlated with ARfl binding at ARv7 sites and at ARfl unique sites, supporting the conclusion that ARv7 is also
256 binding proportionately to ARfl at these latter ARfl unique sites. We also compared ARv7 versus ARfl binding in
257 VCaP16 cells after DHT treatment, and saw a similar strong correlation at ARv7 and ARfl unique sites (**Figure**
258 **5G**). Interestingly, the slope of the line (ratio of ARfl to ARv7 binding) was greater in the DHT-treated cells,
259 consistent with DHT driving stronger binding of ARfl.
260
261 We next reexamined previous ARfl and ARv7 ChIP-seq data in LNCaP95 cells [27] to determine whether ARv7
262 sites identified in VCaP16 cells are similarly higher affinity sites for ARfl and ARv7 in LNCaP95. Indeed, peak
263 intensities with an AR N-terminal Ab, AR C-terminal Ab, and ARv7 Ab were all markedly greater at VCaP16
264 ARv7 sites versus ARfl unique sites (**Figure 5H**). There was also a similar correlation between ARfl and ARv7
265 binding intensities at ARfl unique and ARv7 sites identified in the LNCaP95 cells (**Figure 5I**). Examination of
266 additional AR ChIP-seq data sets in CWR22RV1, LNCaP95, and LNCaP further showed increased ARv7 binding
267 at the ARv7 sites identified in VCaP16 cells, and indicated that these correspond to high affinity ARfl binding
268 sites (**Figure S5A, B, C**). Moreover, an analysis of normal prostate, primary PC clinical samples and PDX CRPC
269 models also showed increased ARfl binding at ARv7 binding sites identified in VCaP16 (**Figure S5D**) [43, 44].
270 Finally, we found that the majority of VCaP16 ARv7 binding sites (89.3%) overlapped ARfl sites that were shared
271 by at least two tumors in an AR ChiP-seq analysis of 88 primary PC [45] (**Figure S5E**).
272
273 We then carried out a motif analysis comparing ARv7 and ARfl binding sites to determine whether identified
274 ARv7 binding sites are associated with distinct features that may mediate increased binding. Notably, relative to
275 ARfl unique sites, the ARv7 sites were greatly enriched for the AR/GR/PR motif, consistent with them being high
276 affinity binding sites (**Figure 5J, Figure S6**). Taken together these results show that the ARv7 and ARfl cistromes
277 in VCaP16 are largely overlapping, and also overlapping with the cistrome of the DHT liganded AR. Moreover,
278 they show that ARv7 binding intensity correlates with affinity for the DHT liganded AR, and that called ARv7 sites
279 in VCaP16 are high affinity ARfl sites across multiple models and clinical samples.
280
281 **ARv7 transcriptome overlaps with that of ARfl**

282 We next compared the initial effects of ENZ treatment in VCaP cells with siRNA-mediated depletion of ARv7 in
283 VCaP16 cells. This showed a very strong correlation between genes regulated by ARfl in VCaP cells and genes
284 regulated by ARv7 in VCaP16 cells, indicating that the ARfl transcriptome in VCaP cells was largely restored by
285 ARv7 in VCaP16 cells (**Figure 6A**). A previous study in LNCaP95 cells had found a marked difference in the
286 ARfl versus ARv7 transcriptomes, with ARv7 acting to suppress expression of a subset of growth promoting
287 genes [27]. Notably, the previous study in LNCaP95 cells compared effects of depleting ARfl versus ARv7, whereas
288 the analysis here compared blocking ARfl in VCaP cells with ARv7 depletion in VCaP16 cells. Therefore, we
289 next compared effects of depleting ARfl versus ARv7 in VCaP16 cells, as was done previously in LNCaP95 cells.
290 In this case there was a much weaker correlation between genes altered in VCaP16 by depletion of ARfl (exon
291 7 siRNA) versus depletion of ARv7 (ARv7 siRNA), with ARfl depletion increasing the expression of many genes
292 that are decreased by ARv7 depletion (**Figure 6B**).
293
294 Similar results were obtained when the AR degrader ARCC-32 was used to deplete ARfl (**Figure 6C**). We also
295 compared effects of an siRNA against exon 1 (targeting both ARfl and ARv7) with siRNA targeting ARfl (exon 7
296 siRNA) (**Figure 6D**) or ARv7 (**Figure 6E**). Notably, the strongest correlation was with the latter ARv7 siRNA,
297 which further supports the conclusion that ARv7 is the predominant driver of AR activity in the VCaP16 cells. We
298 next looked specifically at genes associated with ARv7 binding sites. These were greatly decreased by siRNA
299 targeting both ARfl and ARv7 (Exon 1 siRNA) and by siRNA targeting just ARv7, further showing that these
300 genes are being driven primarily by ARv7 (**Figure 6F**). In contrast, the siRNA targeting just ARfl (Exon 7 siRNA)
301 had a much more modest effect on the ARv7 associated genes, while ARfl depletion with ARCC-32 modestly
302 increased these genes.
303
304 The enhanced expression of many ARv7 stimulated genes and the observed trend towards augmentation in the
305 Hallmark AR Responsive gene set (see Figure 2F) following ARfl depletion were surprising. We hypothesized
306 that this enhancement in VCaP16 cells is a result of coactivator proteins being sequestered by the ENZ-liganded
307 ARfl, and these coactivators become available for ARv7 coactivation upon ARfl depletion. To test this hypothesis,
308 we carried out ChIP-seq for H3K27ac, BRD4, and p300 in VCaP16 cells treated with vehicle or ARCC-32.
309 Consistent with the RNA-seq results, ARCC-32 did not have a clear effect on H3K27Ac at ARv7 or ARfl binding
310 sites (**Figure S7A**). Moreover, it did not have an overall effect on BRD4 at ARv7 or ARfl binding sites (**Figure
311 S7B**). In contrast, p300 binding was decreased (**Figure S7C**). We then examined two directly ARv7 regulated
312 genes (with ARv7 binding sites) whose expression was increased by ARCC-32, GRIN3A and POLR2M (**Figure
313 S7D**). For both genes, enrichment of H3K27Ac and BRD4 at ARv7 binding sites was increased in response to
314 ARCC-32, although p300 was decreased, possibly reflecting a greater role for CBP versus p300 as a coactivator
315 for ARv7 (**Figure S7E, F**). Overall, these findings show that ARfl depletion does not significantly decrease ARv7
316 activity. Instead, it appears to enhance ARv7 activity at a subset of genes, an effect that may be attributed to an
317 increase in coactivator availability.

318

319 Further examination of the genes with called ARv7 binding sites that were altered in response to ARv7 siRNA
320 showed downregulation of multiple canonical AR-regulated genes such as *KLK2* and *KLK3* (**Figure 6G**). These
321 genes were highly enriched for the Hallmark Androgen Response gene set, and also significantly enriched for
322 gene sets related to mTORC1 signaling, TNFα signaling, and lipid metabolism, indicating that ARv7 plays a key
323 role in the restoration of these metabolic functions (**Figure 6H**).

324

325 **ARv7 binding sites are enriched for enhancer marks**

326 The predominant role of ARv7 in driving the AR transcriptome suggested that sites where ARV7 was binding
327 may have particularly strong enhancer activity. Therefore, we next carried out ChIP-seq for marks of active
328 enhancers (H3K27ac and H3K4me1) in VCaP and VCaP16 cells. Indeed, centering on all AR sites in VCaP16
329 cells, H3K27ac was higher at ARv7 sites versus ARfl unique sites (**Figure S8A**). This same finding was observed
330 in VCaP cells, indicating that the sites where ARv7 binds in VCaP16 are also potent enhancers in VCaP, which
331 are presumably being driven by the androgen liganded ARfl. Notably, H3K27ac peak intensities across ARfl
332 unique and ARv7 sites were comparable in VCaP16 versus VCaP cells, consistent with the restoration of AR
333 transcriptional activity in the VCaP16 cells. The results for H3K4me1 were similar to H3K27ac, with increased
334 signal at ARv7 sites in both VCaP16 and VCaP cells (**Figure S8B**). Taken together these data indicate that ARv7
335 sites are enriched for enhancer activity, but do not provide a basis for the gain in ARv7 binding to chromatin in
336 the VCaP16 cells.

337

338 **Adaptation to ENZ is associated with increased chromatin accessibility**

339 We next used ATAC-seq to determine whether the adaptation to ENZ in the VCaP16 cells and gain in ARv7
340 chromatin binding was associated with alterations in chromatin accessibility. Overall, there was an increase in
341 the global intensity and number of ATAC sites in VCaP16 versus VCaP or VCaP-E cells(**Figure 7A, B**). We then
342 identified the subset of ATAC sites that had significantly increased peak intensity in VCaP16 versus VCaP (ATAC
343 UP sites), as well as sites that were not significantly changed and a small number that were decreased in peak
344 intensity (**Figure 7C**). Profile plots indicate that chromatin accessibility at the ATAC UP sites was modestly
345 increased after short term ENZ (VCaP-E cells), and that there was also a modest overall increase in sites
346 identified as unchanged in VCaP16 versus VCaP (Unchanged sites) (**Figure 7D**).

347

348 Notably, while the ATAC-UP sites were only a minority of the total ATAC sites, about 40% of ARv7 sites
349 overlapped with these sites (**Figure 7E**). In contrast, only about 10% of ARfl unique sites overlapped with these
350 ATAC-UP sites. We then assessed ATAC-seq signal centered on ARv7 binding sites, and found this was
351 increased in VCaP16 versus VCaP (**Figure 7F**). In contrast, the ATAC-seq signal at ARfl unique sites was lower
352 and much more modestly increased in the VCaP16 cells. These findings indicated that overall chromatin
353 accessibility was increased in the VCaP16 cells, particularly at ARv7 binding sites.

354

355 The transposase used for ATAC-seq may also generate shorter fragments in areas of chromatin that are
356 nucleosome depleted. Therefore, we next carried out an analysis of ATAC-seq fragment length data to determine
357 whether there were shorter fragments generated at ARv7 sites in VCaP16. However, this analysis did not reveal
358 fragment length differences between ARv7 and ARfl sites in VCaP or VCaP16 cells (**Figure S9**). To further
359 directly test the hypothesis that chromatin around ARv7 sites was more open in VCaP16, we carried out MNase-
360 seq to identify nucleosome protected versus exposed regions. Notably, we found greater depletion of
361 nucleosomes around ARv7 sites in the VCaP16 cells versus the VCaP cells (**Figure 7G**). In contrast, there was
362 no clear difference between VCaP16 and VCaP at ARfl unique sites. Overall, these results indicate that VCaP
363 cells adapt to ENZ through nucleosome depletion around ARv7 binding sites to enhance ARv7 binding.

364

365 We next examined the LuCaP series of PDXs to identify models that may be driven by ARv7 to determine
366 whether they had increased chromatin accessibility at ARv7 sites [46]. We first used a recently published study to
367 identify LuCaP PDXs that had the greatest increases in ARv7 when they relapsed after castration [22]. In parallel
368 we assessed enrichment for a gene set associated with ARv7 [22], which together indicated that the castration-
369 resistant model LuCaP 77CR had the highest ARv7 activity, followed by 105CR and 136CR (**Figure S10A, B**).
370 Finally, we found that one of two LuCaP 77CR and 96CR tumors, and two of two 105CR and 136CR tumors,
371 formed a distinct cluster by unsupervised clustering of ARv7-signature genes expression (**Figure S10C**). Based
372 on these findings, we examined LuCaP 105 versus LuCaP 105CR by ATAC-seq, which showed an overall
373 increase in chromatin accessibility in LuCaP 105CR versus the parental castration-sensitive LuCaP 105 (**Figure**
374 **S11A**). Moreover, ATAC-seq signal at ARfl sites identified in VCaP16 was also increased in the LuCaP 105CR
375 versus parental 105 PDXs, and signal at ARv7 sites identified in VCaP16 was further markedly increased relative
376 to the parental LuCaP 105 PDXs (**Figure S11B**). Together these findings are consistent with similar adaptive
377 mechanisms driving AR reactivation in the PDX models and in VCaP16.

378

379 **Single cell ATAC-seq suggests an intermediate stage in the transition from VCaP to VCaP16**

380 To study chromatin adaptations in VCaP16 versus VCaP on a single cell level, we carried out single cell ATAC-
381 seq (scATAC-seq). Employing K-means clustering on the combined cell data (VCaP, VCaP-E, and VCaP16),
382 we uncovered eight distinct clusters within the chromatin landscape (**Figure S12A**). Notably, cluster 1 was
383 relatively specific to parental VCaP cells, while cluster 3 was relatively specific to VCaP16 cells. An intermediate
384 cluster (cluster 2) was observed across all conditions, positioning itself between clusters 1 and 3 on a t-SNE plot.
385 Our scATAC-seq analysis corroborated our previous findings from bulk ATAC-seq data, demonstrating higher
386 chromatin accessibility at AR motifs in VCaP16 versus VCaP (**Figure S12B, S13A, S13B**). This heightened
387 accessibility was particularly pronounced in the VCaP16 and VCaP-specific clusters (cluster 3 versus cluster 1)
388 (**Figure S12B, S13C**). These findings suggest that the adaptive processes in VCaP16 cells are conducive to
389 unlocking potent AR-binding sites. Notably, the chromatin accessibility analysis also revealed increased

390 accessibility to AR motifs in VCaP-E compared to VCaP cells (**Figure S13A, B**). This observation suggests the
391 initiation of chromatin changes following short-term exposure to ENZ.
392
393 Interestingly, cluster 2, the intermediate cluster that is common across all treatment states, exhibited chromatin
394 features similar to those in cluster 3, specific to VCaP16. This observation leads to the hypothesis that cluster 2
395 may represent a pool of cells driving the development of ENZ resistance, ultimately giving rise to the population
396 seen in cluster 3. To further investigate this hypothesis, we performed trajectory inference analysis. This analysis
397 revealed a pseudotime progression from cluster 1 (VCaP-specific) through cluster 2 (intermediate) to cluster 3
398 (VCaP16-specific) (**Figure S12C**). The trajectory suggests a transition from the VCaP phenotype through an
399 intermediate stage into the VCaP16 phenotype, providing insights into the evolution of ENZ resistance. A
400 complementary analysis using another clustering algorithm revealed the same results (**Figure S14**). Additionally,
401 clusters 4, 5, 6, 7, and 8 exhibited consistent chromatin structures across all cell lines (not shown).
402
403 **ARv7 activity in VCaP16 is dependent on Nuclear Factor I transcription factors**
404 The most highly enriched transcription factor motifs at the ATAC-UP sites in VCaP16 were the common
405 AR/GR/PR/MR motifs (**Figure 8A**). As expected, there was also enrichment for FOXA1, GRHL2, and HOXB13
406 motifs. However, the second most enriched motifs were for Nuclear Factor I (NFI) family transcription factors
407 (NFIA, B, C, X). Comparison with ATAC-Unchanged and ATAC-Down sites similarly showed enrichment for the
408 NFI motif at ATAC-UP sites (**Figure 8B**), and footprint analysis further supported enrichment of NFI transcription
409 factors at ATAC-UP sites (**Figure 8C**).
410
411 We next assessed for enrichment of the ARE, FOXA1, HOXB13, and NFI motifs at ARv7 and ARfl unique sites
412 in VCaP-E cells versus in VCaP16 cells. Notably, while ARE and AR-half motifs were enriched at ARv7 versus
413 ARfl unique sites in both cells, there was greater enrichment of the ARE motif at ARv7 sites in the VCaP-E versus
414 VCaP16 cells, indicating that ARv7 binding was most highly biased towards canonical AREs after short-term
415 ENZ treatment (**Figure 8D**, **Figure S15A**). Conversely, the FOXA1 motif was enriched at ARv7 sites in VCaP16
416 versus VCaP-E cells (**Figure 8E**), while enrichment for the HOXB13 motif was comparable at ARv7 sites in both
417 cell lines (**Figure 8F**). In contrast to the FOXA1 and HOXB13 motifs, enrichment for the NFI motif was seen at
418 ARfl unique versus ARv7 sites in both VCaP-E and VCaP16 cells, with greatest enrichment at ARfl unique sites
419 in VCaP-E cells (**Figure 8G**). One interpretation of this finding is that NFI transcription factors preferentially
420 support ARfl and ARv7 binding at weaker AREs. Therefore next we assessed the NFI motif at AR-binding sites
421 with canonical versus non-canonical AREs, and found a significantly higher enrichment of the motif at non-
422 canonical AREs (**Figure 8H**).
423
424 NFI proteins play major roles in the development of diverse tissues, and can have oncogenic or tumor suppressor
425 functions in varying contexts [47]. Moreover, NFI proteins can bind nucleosomes, control chromatin loop

426 boundaries, and increase chromatin accessibility [48-52]. Notably, previous studies in PC have identified interactions
427 between AR, FOXA1 and NFI proteins, and in particular implicated NFIB in the regulation of AR activity and PC
428 development [53-56]. Examination of the Human Protein Atlas shows that both NFIB and NFIX are highly expressed
429 in prostate (**Figure S16A**), with NFIX being most highly expressed amongst AR-expressing PC cell lines (**Figure**
430 **S16B**). We confirmed by qRT-PCR the preferential expression of NFIX in LNCaP cells, and of NFIX and NFIB
431 in VCaP cells (**Figure S16C**). Consistent with this pattern of expression, DepMap CRISPR and RNAi screens
432 showed dependency on NFIB and NFIX, but not NFIA or NFIC, in AR-positive PC cells (VCaP and 22RV1), with
433 no NFI dependency in AR-negative PC cells (DU145 and PC3) (**Figure S16C - F**). Finally, our RNA-seq data
434 also showed higher NFIB and NFIX (versus NFIA and NFIC) in VCaP and VCaP16, although the difference was
435 more modest and levels for each NFI were comparable in VCaP and VCaP16 cells (**Figure S16G**).
436
437 Based on these data we next assessed the effects of combined siRNA-mediated knockdown of NFIB and NFIX
438 in VCaP16 cells. RNA-seq confirmed that the siRNA decreased both NFIB and NFIX, without compensatory
439 increases in NFIA or NFIC (**Figure S17A**). This NFIB/X depletion did not have a consistent effect on canonical
440 AR-regulated genes, with two such genes (ACPP and NKX3.1) being the most significantly increased and
441 decreased, respectively (**Figure S17B**), and a modest decrease in the Hallmark Androgen Response gene set
442 (**Figure S17C**). Hallmark gene sets related to cell cycle were more significantly decreased (E2F Targets, G2M
443 Checkpoint, and MYC Targets), while there was an increase in the EMT gene set (**Figure S17C**). To more
444 directly assess the contribution of NFI to ARv7 function, we compared the transcriptional effects of NFIB/X versus
445 ARv7 depletion. Notably, these effects were strongly correlated (**Figure 8I**). There was also a correlation
446 between transcriptional effects of ARv7 and FOXA1 knockdown, but the correlation with NFIB/X depletion was
447 greater (**Figure 8J**).
448
449 To further interrogate the role of NFI proteins we looked specifically at expression of genes linked to ARv7
450 binding sites versus ARfl unique sites (which are weak ARv7 sites). There was a correlation between effects of
451 ARv7 and NFIB/X knockdown at the former ARv7-binding site linked genes, and a stronger correlation with the
452 latter ARfl-binding site linked genes, indicating that genes linked to these weaker sites are more dependent on
453 NFIB/X (**Figure S18A**). A similar analysis for FOXA1 siRNA showed weaker correlations for both ARv7- and
454 ARfl-unique site linked genes (**Figure S18B**). Interestingly, while the majority of Hallmark gene sets were
455 decreased by ARv7 knockdown, many gene sets were increased by both FOXA1 and NFIB/X knockdown,
456 suggesting cooperative effects of FOXA1 and NFI transcription factors at many genes that are not AR regulated
457 (**Figure S17C**).
458
459 An overall conclusion from these results is that NFI proteins in ENZ-adapted cells contribute to an increase in
460 chromatin accessibility to support ARv7 and ARfl chromatin binding, particularly at weak AR binding sites that
461 do not have canonical AREs. Based on these observations we examined AR binding sites at genes that were

462 altered by ARv7 siRNA in VCaP16 cells (see figure 6). Notably, only a small fraction of AR binding sites linked
463 to these ARv7 regulated genes had canonical AREs (**Figure S19A**). We next similarly examined AR binding
464 sites at genes that were altered by both depletion of ARv7 and NFIB/X, and found that most also had
465 noncanonical AREs (**Figure S19B**). These findings further support the conclusion that NFI proteins enhance
466 ARv7 activity at weak AREs.
467
468 Interestingly, previous studies have found that the AR cistrome in PC diverges from that in normal prostate
469 epithelium, with AR binding sites in PC being associated with FOXA1 and HOXB13 motifs in PC [43, 44]. Moreover,
470 analysis of AR-binding sites in normal prostate versus primary PC shows that the sites in normal prostate are
471 more highly enriched for canonical full AREs (**Figure S20A**). Notably, in two available data sets we found that
472 the NFI motif was significantly enriched at AR-binding sites in PC versus normal prostate (**Figure 8K**) [43, 57].
473 Furthermore, in both the normal prostate and PC tissues, the NFI motif was enriched at AR binding sites that did
474 not have the canonical full ARE (**Figure S20B, C**). Together these findings indicate that NFI proteins may also
475 contribute to AR reprogramming during PC development. Consistent with this hypothesis, a previous study found
476 that NFIB levels by IHC were increased in PC versus matched normal prostate [53], although analyses of NFIB
477 and NFIX mRNA in multiple data sets do not show clear increases in tumor versus normal tissues (**Figure S20D**).
478

479 **DISCUSSION**

480 ARv7 and related AR variants have constitutive transcription activity and their increased expression is associated
481 with development of resistance to available ASI therapies. However, the extent to which ARv7 drives the AR
482 program, whether it is dependent on ARfl or has other unique dependencies, and whether it has novel functions,
483 remain to be fully determined. To model the progression from androgen-dependence to ENZ resistance in
484 patients we generated VCaP cells that were resistant to ENZ. We found that these VCaP16 cells had features
485 observed most commonly in the clinic including restoration of the AR-transcriptional program, high level of ARfl
486 expression, and increased expression of ARv7. Notably, knockdown or degradation of ARfl did not suppress the
487 AR-transcriptional program in these cells, in contrast to knockdown of ARv7 that did markedly suppress the AR-
488 transcriptional program. Consistent with these results, we showed biochemically that ARv7 complexes on
489 chromatin were not dependent on or associated with ARfl. Significantly, while ARv7 was increased acutely in
490 response to ENZ in the VCaP-E cells, this was not sufficient to drive the AR- transcriptional program. Together
491 these observations indicated that further adaptations are needed to enhance ARv7 binding to chromatin and its
492 ability to drive the AR-transcriptional program.
493
494 We determined that while ARv7 expressed in VCaP-E cells acutely exposed to ENZ was nuclear, it's binding to
495 DNA as assessed by ChIP-seq was low relative to ARv7 in the ENZ-adapted VCaP16 cells. This gain in ARv7
496 chromatin binding in VCaP16 cells was associated with a broad increase in chromatin accessibility as assessed
497 by ATAC-seq. This increase in chromatin accessibility was greater at identified ARv7 binding sites relative to

498 ARfl unique sites, where ARv7 binding is below the peak threshold, and the depletion of nucleosomes at ARv7
499 binding sites in VCaP16 cells versus parental VCaP cells was confirmed by MNase-seq. Transcription factor
500 motifs enriched at sites with increased chromatin accessibility in VCaP16 cells (ATAC-UP sites) included those
501 for AR, FOXA1, and HOXB13, consistent with previous studies showing that FOXA1 and HOXB13 can contribute
502 to AR chromatin binding. However, the most enriched motif at ATAC-UP sites (after the AR motif) was the NFI
503 transcription factor motif. Moreover, the transcriptional effects of depleting NFIB and NFIX in VCaP16 cells were
504 strongly correlated with those of ARv7 depletion. Together these findings indicate a major role for NFI proteins
505 in the enhancement of chromatin accessibility and in supporting ARv7 function.
506
507 Previous studies have shown varying overlap between the cistromes and transcriptomes of ARv7 and ARfl, and
508 indicated that ARv7 may have distinct transcriptional functions [26, 38-42]. However, in LNCaP95 cells (expressing
509 endogenous ARfl and ARv7) we reported previously that all ARv7 binding sites detected by an ARv7 antibody
510 (that were also detected by an AR N-terminal antibody) were also ARfl sites (detected by an AR C-terminal
511 antibody) [27]. We similarly found in VCaP16 cells that the vast majority of called ARv7 sites were also ARfl sites.
512 While these results indicate that the ARv7 cistrome largely mirrors that of ARfl, this certainly does not rule out
513 ARv7 unique sites in some contexts. Indeed, ZFX has been reported to be a novel ARv7 partner that drives
514 ARv7 binding to unique non-canonical sites that are located at promoters and also require BRD4 [58]. Very high
515 levels of ARv7, either endogenous or exogenous, may possibly also drive ARv7 to unique sites. Conversely,
516 some sites recognized by the available ARv7 antibodies may not be specific, particularly if they are not also
517 detected by an AR N-terminal antibody. In other cases, ChIP with AR N-terminal antibody after ARfl knockdown
518 may identify some sites bound by ARv7 that are not strong enough sites to meet statistical thresholds under
519 basal conditions. More studies are clearly needed to understand further mechanisms that may drive ARv7 (or
520 other AR splice variants) to sites that are not bound by the agonist liganded ARfl.
521
522 Notably, the number of ARfl sites in the VCaP16 cells, even in the presence of ENZ, was much greater than the
523 number of called ARv7 sites. This may in part reflect more specific ARfl antibodies for ChIP, so that reads at
524 more sites reach statistical significance over background, and/or intrinsically weaker ARv7 binding. In either
525 case, we found that peak normalized counts for ARv7 were highly correlated with those for ARfl (in VCaP16 and
526 LNCaP95 cells), and this correlation extended to ARfl peaks that were not called as ARv7 sites. These data
527 indicate that the ARv7 cistrome in VCaP16 (and LNCaP95 cells) largely overlaps that of ARfl, but with ARv7
528 having lower affinity and hence with ARv7 binding sites being under called. Indeed, previous FRAP studies have
529 shown that nuclear ARv7 has markedly higher mobility relative to agonist liganded ARfl, indicating a more rapid
530 DNA binding off rate [33, 35]. We propose this relatively weak ARv7 chromatin binding capacity is why adaptations
531 that enhance chromatin accessibility are needed to support its activity in VCaP16 cells.
532

533 With respect to the ARv7 transcriptome, in our current studies we found a strong correlation between genes
534 regulated by ARv7 in VCaP16 cells and those regulated by ARfl in VCaP, supporting the conclusion that ARv7
535 takes over the transcriptional functions of ARfl. In contrast, there was minimal correlation between effects of
536 knockdown of ARv7 versus knockdown or degradation of ARfl. Indeed, ARfl degradation increased expression
537 of many genes that were decreased by ARv7 knockdown. We propose that this reflects increased availability of
538 some coactivator proteins that are being nonproductively engaged by the ENZ-liganded ARfl. Significantly, this
539 coactivator redistribution could mitigate beneficial effects of ARfl degraders that are now being tested in the
540 clinic. Notably, our previous study in LNCaP95 cells did not find a clear correlation between the transcriptional
541 effects of ARv7 versus ARfl knockdown, with ARv7 knockdown increasing expression of some genes that were
542 decreased by ARfl knockdown [27]. Consistent with this previous result in LNCaP95, ARv7 knockdown increased
543 expression of many genes that were decreased by ARfl degradation. This increase may reflect cofactor
544 redistribution, a repressive function of ARv7 at some sites, and/or a greater ability of the ARfl versus ARv7
545 (despite ENZ in the medium) to transactivate at these genes.
546
547 Previous studies have found that compared to ARfl sites, ARv7 sites are associated with open chromatin, with
548 consensus full AREs, and with HOXB13 [40, 41]. Notably, HOXB13, but not FOXA1, has been found to bind directly
549 to ARv7, consistent with an increased dependence on HOXB13 versus FOXA1 (which is associated with and
550 interacts with ARfl) [40, 41, 59, 60]. We similarly found that ARv7-binding sites in VCaP16 were enriched for consensus
551 full AREs relative to ARfl unique sites. Interestingly, this enrichment was greatest in VCaP-E cells, indicating that
552 increased chromatin accessibility in the VCaP16 cells was allowing ARv7 to bind to lower affinity AREs. We
553 similarly found enrichment for the HOXB13 motif at ARv7 sites, but also for the FOXA1 motif. Moreover,
554 enrichment of the FOXA1 motif at ARv7 sites was greater in the VCaP16 cells, supporting a role for FOXA1 in
555 the transition to ARv7 driven ENZ resistance. Notably, in contrast to HOXB13 and FOXA1 motifs, the NFI motif
556 was enriched at ARfl unique versus ARv7 sites. As these ARfl unique sites are also weak ARv7 sites, these
557 findings, in conjunction with the enrichment of NFI at ATAC-UP sites, indicate that NFI plays a major role in the
558 transition to ENZ resistance by depleting nucleosomes and hence broadly facilitating ARv7 binding, and in
559 particular at weak sites. In support of this conclusion, the NFI motif was enriched at AR-binding sites that do not
560 have canonical full ARE in multiple PC models. Moreover, transcriptional effects of ARv7 and NFIB/X depletion
561 were highly correlated, consistent with NFI proteins broadly supporting ARv7 function.
562
563 NFI proteins (NFIA, B, C, X) bind DNA as homo- or heterodimers and can act as pioneer factors by binding to
564 nucleosomes and increasing chromatin accessibility [48-52]. In addition to roles in the development of diverse
565 tissues, they have context dependent oncogenic or tumor suppressor functions [47]. NFIB in small cell lung cancer
566 promotes metastases by broadly increasing chromatin accessibility [48], while NFIB and NFIX in hair follicles act
567 to maintain stem cell super-enhancers [52]. Most recently NFIB was also found to facilitate licensing for DNA
568 replication [61]. Previous studies in PC cells have found an association of NFI proteins with AR-binding sites [54-56]

569 and identified direct interactions between NFI proteins and FOXA1 that can stabilize an AR-FOXA1-NFI complex
570 [55]. In functional studies, NFIB knockdown in LNCaP cells had variable effects on AR-regulated genes, while
571 prostate tissue explants from *Nfib* gene knockout mice showed hyperplasia that may reflect an AR-independent
572 effect as it was not responsive to castration [54]. Our findings are consistent with these previously described
573 interactions between NFI proteins and AR, and reveal a further major role for NFI proteins in the progression to
574 ENZ resistance by increasing chromatin accessibility and supporting ARv7 binding, particularly at sites with weak
575 AREs.
576
577 We further hypothesize that these results reflect a role for NFI proteins in the reprogramming of the AR that
578 occurs during PC development [43], as the NFI motif is significantly enriched at AR-binding sites in PC versus in
579 normal prostate epithelium. Notably, based on mRNA levels, NFI expression is not increased during PC
580 development or the progression to ENZ-resistance, although one IHC study found increased NFIB protein in
581 primary PC to adjacent normal prostate epithelium [53]. However, NFI protein levels or activity may be modulated
582 by alternative splicing or posttranslational mechanisms, with one recent study showing that arginine methylation
583 by CARM1 facilitates the NFIB-mediated maintenance of open chromatin states in small cell lung cancer [62].
584 Further studies to address NFI expression and activity during PC development and progression are warrented.
585
586 **METHODS**
587 **Cell Culture**
588 VCaP cells (ATCC, Manassas, VA) were maintained in DMEM with 10% fetal bovine serum (FBS). LNCaP95
589 cells [63] were maintained in RPMI 1640 medium supplemented with 10% charcoal/dextran-stripped fetal bovine
590 serum (CSS), 1% L-Glutamine and 1% penicillin/streptomycin. Cell line identities were established by short
591 tandem repeat profiling and interspecies contamination test (IDEXX). Cells were screened for mycoplasma with
592 MycoAlert detection kit (Lonza) at receipt or thaw, and then monthly for the duration of project. Cells were
593 employed for 20 passages only before new cell lines were thawed. For generation of VCaP16 ENZ-resistant
594 model, we seeded cells on plates in standard parental media and, after overnight attachment, switched to
595 medium with 2-fold increasing concentrations of ENZ, ending at 16 μM ENZ after ~ 2 months. The VCaP16 cells
596 were maintained in 16 μM ENZ, and medium on all cell models was changed every 2-3 days.
597
598 **Immunoblotting and immunoprecipitation**
599 For immunoblotting cells were harvested in RIPA lysis buffer supplemented with a protease and phosphatase
600 inhibitor cocktails (Thermo Fisher). Lysis was allowed to proceed for 30-60 minutes on ice, before cells were
601 spun down at maximum RPM in a microfuge and cell debris pellets removed. Protein concentrations were
602 determined by Bicinchoninic acid (BCA) assay (Thermo Fisher). Lysates were prepared with 4X Laemmli buffer
603 (BioRad, #1610747) and β-mercaptoethanol. Samples were run on pre-cast 4-15% gradient gels (BioRad), and
604 fast-transferred to nitrocellulose membranes using the TransBlot Turbo system (BioRad). Separation of cells into

605 cytoplasmic, soluble nuclear, and chromatin fractions was carried out using a Subcellular Protein Fractionation
606 Kit (Thermo Fisher #78840).
607
608 For assessment of ARv7/ARfl interaction, cells were incubated in PBS with 1.5 mM dithiobis (succinimidyl
609 propionate) (DSP, Thermo Fisher #22585) for 20 min, followed by incubation in 1% formaldehyde for 10 min at
610 room temperature. Cross-linking was quenched by adding glycine to 0.1 M. Cell nuclei were then extracted and
611 resuspended in 1/2 dilution IP buffer (Thermo Fisher #87788) and sonicated for 2 min (5s on/5s off) in a
612 Diagenode Bioruptor in 4 ℃ water bath with medium power setting. The sample was combined with 10×TBS and
613 10% Triton X-100 to give final concentration of 1X TBS/1%Triton X-100, and 100 mM $MgCl_2$ was added to give
614 1 mM $MgCl_2$ final concentration. Benzonase (Sigma #71205) was then added (90 U per 50 μL, which was
615 determined to be optimum in initial studies) [31]. Benzonase digestion was for 15 min at 37℃ on a 750 RPM shaker,
616 and then 50 μL of each aliquot was processed for reverse cross-linking, followed by immunoblotting.
617
618 **Antibodies and Reagents**
619 The antibodies and concentrations used for immunostaining and immunoblotting blotting were: anti-Vinculin
620 (Santa Cruz Biotechnology, #sc-73614, 1:5000), anti-GAPDH (Cell Signaling Technologies, #5174S, 1:5000),
621 anti-AR (NT) (RevMab Biosciences, #31-1135-00, 1:2000), anti-ARv7 (RevMAb Biosciences, #31-1109-00,
622 1:2000), anti-CBP-P300 (Thermo-Fisher, #MA5-13634, 1:50 for IF, 1:2000 for WB), anti-FOXA1 (Cell Signaling
623 Technologies, #53528S, Rabbit Host, 1:2000), anti-FOXA1 (Sigma, #WH0003169M1, Mouse Host, 1:2000),
624 anti-PSA (Cell Signaling Technologies, #5365S, 1:2000), anti-H3 (Cell Signaling Technologies, #4499S,
625 1:2000). The siRNA for non-targeting control (Dharmacon, #D-001810-01-05), ARfl (exon 7, Dharmacon,
626 #VOZOB-000001, UCAAGGAACUCGAUCGUAUUU), ARv7 (Dharmacon, #SRYWD-000001,
627 GUAGUUGUAUCAUGAUU) or both (exon1, Dharmacon, #SRYWD-000005, CAAGGGAGGUUACACCAAAUU)
628 were purchased from Dharmacon. Enzalutamide was obtained from SelleckChem (TX, USA). AR degrader
629 ARCC-32 was provided by Arvinus Pharmaceuitcals. RIPA buffer and Triton-X100 were purchased from Thermo
630 Fisher. RNaseA and Dynabeads were purchased from Invitrogen.
631
632 **Immunofluorescence**
633 Cells were fixed with 4% paraformaldehyde at room temperature on a rocker in the dark, and then washed three
634 times with PBS. Fixed cells were washed with TBS and permeabilized with 0.1% Triton X-100 for 10 minutes at
635 room temperature. After three washes with TBS, the sections were incubated with 5% normal donkey serum
636 (Jackson ImmunoResearch Lab Inc, West Grove, PA) for an hour at room temperature. Slides were then
637 incubated with mouse anti-Androgen Receptor C-terminal (ARfl) (1:100, Abcam #ab227678), rabbit anti-ARv7
638 (1:200, RevMab Biosciences, 31-1109-00), and mouse anti-CBP/p300 monoclonal antibody (NM11, Thermo-
639 Fisher MA5-13634) overnight at 4°C. The slides were washed three times and incubated with Alexa Fluor 647
640 conjugated donkey anti-mouse secondary antibody (Jackson ImmunoResearch Lab, 1:300) or Cy3 conjugated

641 donkey anti-rabbit secondary antibody (Jackson ImmunoResearch Lab, 1:300). Samples were counterstained
642 with Hoechst 33342 (Invitrogen) and washed three times with TBS. The slides were mounted with Prolong Gold
643 anti-fade mounting media (Invitrogen). A Zeiss LSM 880 Inverted Live-cell Laser Scanning Confocal Microscope
644 with Airyscan module was employed for all imaging. Z-stack images were captured for all markers to generate a
645 3D dataset for quantification with Imaris 9.8.2 software (Oxford Instruments).
646

647 **Quantitative real-time PCR**

648 RNA was extracted from cell lines using an RNeasy Plus kit (Qiagen) according to the manufacturer's
649 instructions. Subsequent qPCR was performed using the TaqMan Fast Virus 1-Step Master Mix and
650 StepOnePlus Real-Time PCR System (Thermo Fisher). The primers purchased from TaqMan were: GAPDH
651 (Thermo Fisher, #4310884E), AR-FL (Thermo Fisher, Hs001711772_m1), AR-v7 (Thermo Fisher, #4331348,
652 Custom Assay ID: AI6ROCI), KLK3 (Thermo Fisher, Hs02576345_m1), KLK2 (Thermo Fisher,
653 Hs00428383_m1), FKBP5 (Thermo Fisher, Hs01561006_m1), TMPRSS2 (Thermo Fisher, hs01120965_m1),
654 and SLC45A3 (Thermo Fisher, Hs01026319_g1).
655

656 **Proliferation Assays**

657 For proliferation of VCaP cells exposed to ENZ, cells were plated at 20,000 cells/well on day -2 . Experimental
658 and control treatments were conducted and initial readings taken on day 0. CyQuant® Direct Cell Proliferation
659 Assay (Invitrogen) was employed for determination of cell number based on fluorescent DNA staining, with dead
660 cell exclusion provided by CyQuant® Suppressor solution (Invitrogen). An equal volume of CyQuant® solution,
661 prepared on treatment day, was added to cells in culture medium, incubated for 60 minutes at 37°C, and
662 fluorescence read on a SpectraMAX iD3 microplate reader (excitation/emmission 485nm/525nm). To assess
663 effects of depleting ARfl or ARv7, cells were treated with siARv7, ARCC-32 (obtained from Arvinas, New Haven,
664 CT), or vehicle on days 0 and 4.
665

666 **siRNA Transfection**

667 Transfection with RNAiMAX reagents (Invitrogen) was conducted per manufacturer's instructions for up to 72
668 hours. The siRNA for non-targeting control (Dharmacon, #D-001810-01-05), ARfl (exon 7, Dharmacon,
669 #VOZOB-000001, UCAAGGAACUCGAUCGUAUUU), ARv7 (Dharmacon, #SRYWD-000001,
670 GUAGUUGUAUCAUGAUU) or both (exon1, Dharmacon, #SRYWD-000005, CAAGGGAGGUUACACCAAAUU)
671 were purchased from Dharmacon.
672

673 **ChIP-Sequencing**

674 ChIP-seq was performed as previously described [27]. The cells were cultured and plated to ensure they reached
675 a healthy confluency of 90% on 10 cm plates before crosslinking. Briefly, cells were crosslinked with 1%
676 formaldehyde (single fixation) or 2 mM fresh disuccinimidyl glutarate and 1% formaldehyde (double fixation) and

677 then chromatin sonicated to 200–600 bp. ChIP was carried out using antibodies against H3K27Ac (Diagenode,
678 C15410196), H3K4me1 (Abcam, ab8895), C-terminal ARfl (Spring Bioscience, clone SP242), ARv7 (RevMAb
679 Biosciences USA Inc., 31-1109-00), FOXA1 (Cell Signaling Technologies, 53528S), BRD4 (Diagenode,
680 C15410337), p300 (Cell Signaling Technologies, 57625S) and then conjugation to Protein A and G Dynabeads
681 (Thermo Fisher Scientific). ChIP DNA was purified using the ChIP DNA Clean & Concentrator™ Kit (Zymo
682 Research, D5205). ChIP-seq libraries were generated using the ThruPLEX DNA-seq Kit (Rubicon Genomics),
683 Accel-NGS 2S Plus DNA Libraries Kit with Unique Dual Indexing (Swift Biosciences, 29096/290384) or
684 SimpleChIP ChIP-seq Multiplex Oligos for Illumina with Dual Index Primers (Cell Signaling Technology, 47538)
685 according to the manufacturer's instructions. Libraries were pooled and sequenced on the Illumina NextSeq500
686 platform at the Molecular Biology Core Facility (DFCI) or NovaSeq6000 platform at the Novogene (Sacramento,
687 CA)
688
689 **MNase-Sequencing**
690 MNase-seq was performed as previously described [64]. VCaP and VCaP16 cells were cultured in complete DMEM
691 media supplemented with 10% FBS and 1% Penicillin (5000 IU/ml)-Streptomycin (5000 µg/ml) solution. VCaP16
692 cells were cultured with the addition of 16 μM ENZ. Twenty-four hours prior to harvesting, fresh culture medium
693 was added. Cells were crosslinked with 1% formaldehyde and then 2.5 x 10^6 cells were treated with 60 U of
694 MNase (Worthington, LS004797) and Exonuclease III (E. coli) (New England BioLab, M0206S). DNA was
695 purified using ChIP DNA Clean & Concentrator™ Kit (Zymo Research, D5205). Libraries were generated using
696 the SimpleChIP ChIP-seq Multiplex Oligos for Illumina with Dual Index Primers (Cell Signaling Technology,
697 47538) according to the manufacturer's instructions. Libraries were pooled and sequenced on the NovaSeq6000
698 platform at the Novogene (Sacramento, CA).
699
700 **ATAC-seq**
701 For bulk ATAC-seq cells were crosslinked with fresh 1% formaldehyde for 10 minutes, then quenched with
702 glycine and frozen. Cells were thawed in cold ATAC-seq buffer (ASB, 10 mM Tris-HCl pH 7.4, 10 mM NaCl, and
703 3 mM $MgCl_2$) and centrifuged. Cells were lysed by resuspension in .05 mL of lysis buffer (ASB with 0.1% NP40,
704 0.1% Tween-20, and 0.01% digitonin), followed by addition of 1 mL ASB with 0.1% Tween-20 and centrifugation.
705 Nuclei were resuspended in 50 µL tagmentation reaction containing 25 μL 2X tagmentation buffer (Illumina
706 15027866), 16.5 μL PBS, 0.5 μL Tween-20, 0.5 μL 1:1 water diluted digitonin, 2.5 μL Tn5 transposase (Illumina
707 15027865), and 5 μL water, and incubated at 37°C for 30 minutes. Transposed DNA was purified using Qiagen
708 columns. Libraries were amplified and sequencing was performed in thirty-five base pair paired-end reads on a
709 NextSeq instrument (Illumina). For single cell ATAC-seq, approximately 7000 cells were targeted for each
710 sample and processed according to the 10X Genomics scATAC-seq sample preparation protocol (Chromium
711 Single Cell ATAC Library & Gel Bead Kit, 10Å~ Genomics). Libraries were sequenced as paired-end reads on a
712 NextSeq instrument (Illumina).

713

714 **RNA-seq analysis**

715 Total RNA was isolated using the RNeasy Plus Kit (Qiagen) following the manufacturer's instructions. mRNA
716 libraries were generated using the Illumina TruSeq stranded mRNA sample kit. Raw reads were analyzed using
717 a pipeline for RNA-seq analysis - Visualization Pipeline for RNA-seq analysis (VIPER) based on workflow
718 management system Snakemake (https://github.com/hanfeisun/viper-rnaseq). The read alignment to hg19
719 reference genome was performed using STAR aligner (2.7.0f) with default parameters. Gene expression (FPKM
720 values) was quantitated with Cufflinks (v2.2.1). Bedtools (v2.27.1) genomecov and bedGraphToBigWig v 4 were
721 used to generate bigwig files.

722

723 **ChIP-seq analysis**

724 The data was analyzed using a pipeline CHromatin enrIchment ProcesSor Pipeline (CHIPS) based on workflow
725 management system Snakemake (https://github.com/liulab-dfci/CHIPS) unless otherwise stated. Raw reads
726 were aligned to hg19 reference genome using Burrows-Wheeler Aligner (bwa mem) 0.7.15-r1140 with default
727 parameters; MACS2 algorithm (2.2.7.1) was used to call peaks; MACS2 (2.2.7.1) and bedGraphToBigWig (v 4)
728 were used to generate bigwig files. Read counts for downstream analyses were quantified using the
729 bioliquidator/bamliquidator tool from Docker image (https://hub.docker.com/r/bioliquidator/bamliquidator).
730 Genomic regions were annotated using Hypergeometric Optimization of Motif EnRichment tool (HOMER v3.12).
731 Motif enrichment analysis was performed using HOMER v3.12. Output bam files (from CHIPS pipeline) for ARv7
732 and ARfl in VCaP and VCaP16 cells were used for secondary peak calling with HOMER v3.12 to generate bed
733 files that were used for further downstream analysis. Bigwig files for samples with biological duplicates were
734 averaged using a combination of the wiggletools and wigToBigWig tools.

735

736 **MNase-seq analysis**

737 The raw sequencing data underwent analysis using a modified version of the nf-core/mnaseseq pipeline. Raw
738 reads were mapped to hg19 with Burrows-Wheeler Aligner 0.7.8 (bwa mem) with default parameters. Unmapped
739 reads, not primary reads, reads aligned to different locations and low-quality reads were filtered out with samtools
740 1.9. Bibwig files were generated with deeptools 3.0.2. Profile plots and heatmaps were generated with deeptools
741 3.0.2 to visualize the nucleosome footprints.

742

743 **WES analysis**

744 Genomic DNA was isolated using DNeasy Blood & Tissue Kit (Qiagen). Libraries for Whole Exome Sequencing
745 (WES) were prepared, and the sequencing was performed on NovaSeq6000 platform at the Novogene
746 (Sacramento, CA) aiming for 100X coverage. The analysis of WES data followed the established Genome
747 Analysis Toolkit (GATK 4.1.9.0) Best Practices Workflows. The raw reads were aligned to the hg38 reference
748 genome using the Burrows-Wheeler Aligner (BWA) version 0.7.8. The identification of candidate somatic variants

749 was carried out using the Mutect2 function from GATK version 4.1.9.0. Identified somatic variants were
750 annotated using Funcotator, which is a part of GATK 4.1.9.0. ANNOVAR (ANNOtate VARiation) tool was utilized
751 for the interpretation and prioritization of the filtered somatic variants. To assess copy ratio alterations, we
752 employed a suite of functions from GATK 4.1.9.0, including PreprocessIntervals, CollectReadCounts,
753 DenoiseReadCounts, and PlotDenoisedCopyRatios, which also allowed for visualization of the data.
754

755 **ATAC-seq analysis**

756 The data were analyzed using a pipeline CHromatin enrIchment ProcesSor Pipeline (CHIPS) based on workflow
757 management system Snakemake (https://github.com/liulab-dfci/CHIPS) and Containerized Bioinformatics
758 workflow for Reproducible ChIP/ATAC-seq Analysis (CoBRA) (https://bitbucket.org/cfce/cobra; cfce-
759 cobra.readthedocs.io/en/latest/).
760

761 **scATAC-seq analysis**

762 The raw FASTQ files underwent preprocessing using the Cell Ranger ATAC pipeline, version 1.2.0, provided by
763 10X Genomics (https://support.10xgenomics.com/single-cell-atac/software). The data was aligned to hg19.
764 Dimensionality reduction was achieved using Latent Semantic Analysis (LSA) applied to the filtered peak-
765 barcode matrices. The data was divided into 8 clusters through k-means clustering. Visualization of these
766 clusters was performed using t-distributed stochastic neighbor embedding (t-SNE). For gene annotations, the
767 GENCODE Gene track, version 28lift37, was utilized. For further downstream analysis and visualization of
768 scATAC-Seq data, the Loupe Browser, version 6.5.0, was employed. Signac and Seurat R packages were used
769 to complement the analysis. Latent Semantic Indexing (LSI) dimensionality reduction was applied for the Uniform
770 Manifold Approximation and Projection (UMAP) algorithm. Clusters were defined using the Spectral Latent
771 Manifold (SLM) algorithm. Trajectory Inference: To uncover the global structure of the identified clusters and
772 convert this structure into smooth lineages represented by pseudotime, the Slingshot algorithm (Trajectory
773 Inference for Single-Cell Data) was employed.
774

775 **DATA AVAILABILITY**

776 Public datasets used in this publication are available at GEO via the provided accession numbers: AR ChIP-seq
777 data GSE106561 (GSM2842708, GSM2842700, GSM2842704), GSE99378 (GSM2643239, GSM2643240,
778 GSM2643241, GSM2643242, GSM2643245, GSM2643246, GSM2643247, GSM2643248), GSE143906
779 (GSM4276560, GSM4276561), GSE130408 (GSM4569829 – GSM4569867), GSE39879 (GSM980655,
780 GSM980664), GSE137527 (GSM4081278 – GSM4081325); RNA-seq data GSE126078;expression profiling by
781 array GSE21034 (GSM526290 – GSM5262318, GSM526265 – GSM526283, GSM526134 – GSM526264).
782 Genomic data generated in this study are deposited in GEO under the accession number GSE252902.
783

784 **ACKNOWLEDGMENTS**

This work was supported by NCI P01 CA163227 (MB, PSN, EC, HL, SPB), NCI P50 CA272390 (MB, SPB), NCI U54 CA156732 (SPB), NCI R01CA272934 (SPB), DoD PCRP Idea Award W81XVVH-20-100925 (SPB), Koch Institute-Dana Farber/Harvard Cancer Center Bridge Project Award (SPB), and a Prostate Cancer Foundation Challenge Award (SPB). JWR was supported by a Prostate Cancer Foundation Young Investigator Award (18YOUN24) and DoD PCRP Early Investigator Award (W81XWH-18-1-0531). AV was supported by a DoD PCRP Physician Research Award (PC200820) and ASCO (Young Investigator Award, 2021A010981). NAL was supported by funding from TUBITAK (114Z491), DoD (W81XWH-21-1-0234) and CIHR (PJT-173331). AGS was supported by the Intramural Research Program of the National Cancer Institute, NIH. MLF was supported by the Claudia Adams Barr Program for Innovative Cancer Research, the Dana-Farber Cancer Institute Presidential Initiatives Fund, the H.L. Snyder Medical Research Foundation, the Cutler Family Fund for Prevention and Early Detection, the Donahue Family Fund, DoD (W81XWH-21-1-0339, W81XWH-22-1-0951), NIH (R01CA251555, R01CA227237, R01CA262577, R01CA259058) and a Movember PCF Challenge Award. We thank Dr. Stephen Plymate for thoughtful input during the course of these studies.

CONFLICTS OF INTEREST

PSN has received consulting fees from Janssen, Merck and Bristol Myers Squibb and research support from Janssen for work unrelated to the present studies. No conflicts are reported by the other authors.

804 **REFERENCES**

805 1. Stanbrough, M. *et al.* Increased expression of genes converting adrenal androgens to testosterone in
806 androgen-independent prostate cancer. *Cancer Res* **66**, 2815-2825 (2006).
807 2. Montgomery, R.B. *et al.* Maintenance of intratumoral androgens in metastatic prostate cancer: a
808 mechanism for castration-resistant tumor growth. *Cancer Res* **68**, 4447-4454 (2008).
809 3. Penning, T.M. & Detlefsen, A.J. Intracrinology-revisited and prostate cancer. *J Steroid Biochem Mol Biol*
810 **196**, 105499 (2020).
811 4. Smith, M.R. *et al.* Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. *N Engl J Med*
812 **378**, 1408-1418 (2018).
813 5. Beer, T.M. *et al.* Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J Med* **371**,
814 424-433 (2014).
815 6. Ryan, C.J. *et al.* Abiraterone in metastatic prostate cancer without previous chemotherapy. *N Engl J Med*
816 **368**, 138-148 (2013).
817 7. Bluemn, E.G. *et al.* Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF
818 Signaling. *Cancer Cell* **32**, 474-489 e476 (2017).
819 8. Beltran, H. *et al.* Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. *Nat*
820 *Med* **22**, 298-305 (2016).
821 9. Takeda, D.Y. *et al.* A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in
822 Advanced Prostate Cancer. *Cell* **174**, 422-432 e413 (2018).
823 10. Viswanathan, S.R. *et al.* Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed
824 by Linked-Read Genome Sequencing. *Cell* **174**, 433-447 e419 (2018).
825 11. Quigley, D.A. *et al.* Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. *Cell* **174**,
826 758-769 e759 (2018).
827 12. Chen, E.J. *et al.* Abiraterone treatment in castration-resistant prostate cancer selects for progesterone
828 responsive mutant androgen receptors. *Clin Cancer Res* **21**, 1273-1280 (2015).
829 13. Varkaris, A., Stevens, J., Ono, Y., Balk, S.P. & Bellmunt, J. A Case of Prostate Cancer Harboring
830 Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate
831 Treatment Responding to Darolutamide. *JCO Precis Oncol* **6**, e2100091 (2022).
832 14. Taplin, M.E. *et al.* Selection for androgen receptor mutations in prostate cancers treated with androgen
833 antagonist. *Cancer Res* **59**, 2511-2515 (1999).
834 15. Balbas, M.D. *et al.* Overcoming mutation-based resistance to antiandrogens with rational drug design.
835 *Elife* **2**, e00499 (2013).
836 16. Korpal, M. *et al.* An F876L mutation in androgen receptor confers genetic and phenotypic resistance to
837 MDV3100 (enzalutamide). *Cancer Discov* **3**, 1030-1043 (2013).
838 17. Einstein, D.J., Arai, S. & Balk, S.P. Targeting the androgen receptor and overcoming resistance in
839 prostate cancer. *Curr Opin Oncol* **31**, 175-182 (2019).
840 18. Dehm, S.M., Schmidt, L.J., Heemers, H.V., Vessella, R.L. & Tindall, D.J. Splicing of a novel androgen
841 receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy
842 resistance. *Cancer Res* **68**, 5469-5477 (2008).
843 19. Antonarakis, E.S. *et al.* AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. *N Engl*
844 *J Med* **371**, 1028-1038 (2014).
845 20. Sun, S. *et al.* Castration resistance in human prostate cancer is conferred by a frequently occurring
846 androgen receptor splice variant. *J Clin Invest* **120**, 2715-2730 (2010).
847 21. Sharp, A. *et al.* Androgen receptor splice variant-7 expression emerges with castration resistance in
848 prostate cancer. *J Clin Invest* **129**, 192-208 (2019).
849 22. Sowalsky, A.G. *et al.* Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical
850 Response in Castration-Sensitive Prostate Cancer. *Clin Cancer Res* **28**, 3509-3525 (2022).
851 23. Armstrong, A.J. *et al.* Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and
852 Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY
853 Study. *J Clin Oncol* **37**, 1120-1129 (2019).
854 24. Guo, Z. *et al.* A novel androgen receptor splice variant is up-regulated during prostate cancer progression
855 and promotes androgen depletion-resistant growth. *Cancer Res* **69**, 2305-2313 (2009).
856 25. Hu, R. *et al.* Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify
857 hormone-refractory prostate cancer. *Cancer Res* **69**, 16-22 (2009).

858 26. Li, Y. *et al.* Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant
859 prostate cancer cell lines. *Cancer Res* **73**, 483-489 (2013).
860 27. Cato, L. *et al.* ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer.
861 *Cancer Cell* **35**, 401-413 e406 (2019).
862 28. Scher, H.I. *et al.* Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker
863 With Outcomes and Survival in Castration-Resistant Prostate Cancer. *JAMA Oncol* **2**, 1441-1449 (2016).
864 29. Xu, Y., Chen, S.Y., Ross, K.N. & Balk, S.P. Androgens induce prostate cancer cell proliferation through
865 mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins. *Cancer*
866 *Res* **66**, 7783-7792 (2006).
867 30. Yu, Z. *et al.* Rapid induction of androgen receptor splice variants by androgen deprivation in prostate
868 cancer. *Clin Cancer Res* **20**, 1590-1600 (2014).
869 31. Liang, J. *et al.* Androgen receptor splice variant 7 functions independently of the full length receptor in
870 prostate cancer cells. *Cancer Lett* (2021).
871 32. Xu, D. *et al.* Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes. *Cancer Res*
872 **75**, 3663-3671 (2015).
873 33. Ozgun, F. *et al.* DNA binding alters ARv7 dimer interactions. *J Cell Sci* **134** (2021).
874 34. Roggero, C.M. *et al.* A detailed characterization of stepwise activation of the androgen receptor variant
875 7 in prostate cancer cells. *Oncogene* **40**, 1106-1117 (2021).
876 35. Kim, S. *et al.* AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement
877 in castrate-resistant prostate cancer. *Elife* **11** (2022).
878 36. Voss, T.C. *et al.* Dynamic exchange at regulatory elements during chromatin remodeling underlies
879 assisted loading mechanism. *Cell* **146**, 544-554 (2011).
880 37. Arora, V.K. *et al.* Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen
881 receptor blockade. *Cell* **155**, 1309-1322 (2013).
882 38. Lu, J. *et al.* The cistrome and gene signature of androgen receptor splice variants in castration resistant
883 prostate cancer cells. *J Urol* **193**, 690-698 (2015).
884 39. Chan, S.C. *et al.* Targeting chromatin binding regulation of constitutively active AR variants to overcome
885 prostate cancer resistance to endocrine-based therapies. *Nucleic Acids Res* **43**, 5880-5897 (2015).
886 40. Chen, Z. *et al.* Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
887 *Proc Natl Acad Sci U S A* **115**, 6810-6815 (2018).
888 41. He, Y. *et al.* Androgen receptor splice variants bind to constitutively open chromatin and promote
889 abiraterone-resistant growth of prostate cancer. *Nucleic Acids Res* **46**, 1895-1911 (2018).
890 42. Krause, W.C., Shafi, A.A., Nakka, M. & Weigel, N.L. Androgen receptor and its splice variant, AR-V7,
891 differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. *Int J Biochem Cell Biol* **54**,
892 49-59 (2014).
893 43. Pomerantz, M.M. *et al.* The androgen receptor cistrome is extensively reprogrammed in human prostate
894 tumorigenesis. *Nat Genet* **47**, 1346-1351 (2015).
895 44. Pomerantz, M.M. *et al.* Prostate cancer reactivates developmental epigenomic programs during
896 metastatic progression. *Nat Genet* **52**, 790-799 (2020).
897 45. Kneppers, J. *et al.* Extensive androgen receptor enhancer heterogeneity in primary prostate cancers
898 underlies transcriptional diversity and metastatic potential. *Nat Commun* **13**, 7367 (2022).
899 46. Nguyen, H.M. *et al.* LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular
900 Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics. *Prostate*
901 **77**, 654-671 (2017).
902 47. Chen, K.S., Lim, J.W.C., Richards, L.J. & Bunt, J. The convergent roles of the nuclear factor I transcription
903 factors in development and cancer. *Cancer Lett* **410**, 124-138 (2017).
904 48. Denny, S.K. *et al.* Nfib Promotes Metastasis through a Widespread Increase in Chromatin Accessibility.
905 *Cell* **166**, 328-342 (2016).
906 49. Chavez, S. & Beato, M. Nucleosome-mediated synergism between transcription factors on the mouse
907 mammary tumor virus promoter. *Proc Natl Acad Sci U S A* **94**, 2885-2890 (1997).
908 50. Ferrari, S. *et al.* Chromatin domain boundaries delimited by a histone-binding protein in yeast. *J Biol*
909 *Chem* **279**, 55520-55530 (2004).
910 51. Pjanic, M. *et al.* Nuclear Factor I genomic binding associates with chromatin boundaries. *BMC Genomics*
911 **14**, 99 (2013).

912 52. Adam, R.C. *et al.* NFI transcription factors provide chromatin access to maintain stem cell identity while
913 preventing unintended lineage fate choices. *Nat Cell Biol* **22**, 640-650 (2020).
914 53. Nanda, J.S. *et al.* Increased nuclear factor I/B expression in prostate cancer correlates with AR
915 expression. *Prostate* **80**, 1058-1070 (2020).
916 54. Grabowska, M.M. *et al.* Nfib Regulates Transcriptional Networks That Control the Development of
917 Prostatic Hyperplasia. *Endocrinology* **157**, 1094-1109 (2016).
918 55. Grabowska, M.M. *et al.* NFI transcription factors interact with FOXA1 to regulate prostate-specific gene
919 expression. *Mol Endocrinol* **28**, 949-964 (2014).
920 56. Jia, L. *et al.* Genomic androgen receptor-occupied regions with different functions, defined by histone
921 acetylation, coregulators and transcriptional capacity. *PLoS One* **3**, e3645 (2008).
922 57. Mazrooei, P. *et al.* Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants
923 on Master Transcription Regulators in Primary Prostate Tumors. *Cancer Cell* **36**, 674-689 e676 (2019).
924 58. Cai, L. *et al.* ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant
925 7 in Castrate-Resistant Prostate Cancer. *Mol Cell* **72**, 341-354 e346 (2018).
926 59. Jin, H.J., Zhao, J.C., Wu, L., Kim, J. & Yu, J. Cooperativity and equilibrium with FOXA1 define the
927 androgen receptor transcriptional program. *Nat Commun* **5**, 3972 (2014).
928 60. Gao, N. *et al.* The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor
929 in transcriptional regulation of prostatic genes. *Mol Endocrinol* **17**, 1484-1507 (2003).
930 61. Zhang, W. *et al.* NFIB facilitates replication licensing by acting as a genome organizer. *Nat Commun* **14**,
931 5076 (2023).
932 62. Gao, G. *et al.* The NFIB/CARM1 partnership is a driver in preclinical models of small cell lung cancer.
933 *Nat Commun* **14**, 363 (2023).
934 63. Hu, R. *et al.* Distinct transcriptional programs mediated by the ligand-dependent full-length androgen
935 receptor and its splice variants in castration-resistant prostate cancer. *Cancer Res* **72**, 3457-3462 (2012).
936 64. McKnight, L.E. *et al.* Rapid and inexpensive preparation of genome-wide nucleosome footprints from
937 model and non-model organisms. *STAR Protoc* **2**, 100486 (2021).

938

939

Figure 1


A
OD (485nm/535nm)
1×10⁷
8×10⁶
6×10⁶
4×10⁶
2×10⁶
0
***
*
VCaP
VCaP-E
VCaP16
B
mRNA Fold Change
KLK3
KLK2
FKBP5
NKX3.1
**
*
*
**
VCaP
VCaP-E
VCaP16
C
VCaP-E vs VCaP
HALLMARK_ANDROGEN_RESPONSE
Enrichment score (ES)
FDR: 0
NES: -2.3608
Positive
VCaP-E vs VCaP
Negative
Ranking metric
Rank in ordered gene list
VCaP16 vs VCaP
HALLMARK_ANDROGEN_RESPONSE
FDR: 0.9707
NES: 0.6906
Positive
VCaP16 vs VCaP
Negative
Rank in ordered gene list
D
VCaP
VCaP16
AR-NT
AR-NT
ARv7
PSA
Vinculin
100 KDa
75 KDa
100 KDa
75 KDa
75 KDa
E
VCaP
VCaP16
mRNA Fold Change
**
ARfl
ARv7

941 **Figure 1. VCaP16 cells exhibit increased ARv7 expression and resistance to AR blockade. A)** Cell
942 proliferation assay for VCaP, VCaP treated with 16 μM ENZ (VCaP-E), and VCaP16 (maintained in 16 μM ENZ)
943 at 7 days post-treatment (*p<0.05, **p<0.01, ANOVA). **B)** Expression of AR-regulated genes *KLK3*, *KLK2*,
944 *FKBP5*, *NKX3.1* assessed by qRT-PCR in VCaP16, VCaP cells treated with ENZ for 4 days (VCaP-E), and
945 parental VCaP cells (* p<0.05, **p<0.01, Mann-Whitney U). **C)** Enrichment plots for Hallmark Androgen
946 Response gene set by GSEA comparing RNA-seq for VCaP cells treated with ENZ for 4 days (VCaP-E) or
947 VCaP16 versus parental VCaP. Significantly differentially expressed genes (adjusted p-value < 0.05) were used
948 as an input. **D)** Immunoblot of protein from VCaP16 and parental VCaP cells. **E)** Expression of ARfl and ARv7
949 assessed by qRT-PCR in VCaP (black) and VCaP16 (red) cells (*p<0.05, **p<0.01, Unpaired t-test, two-tailed).

950

Figure 2


A
KLK3
mRNA Fold Change
1.25
1.00
0.75
0.50
0.25
0.00
ns
**
*
siNTC
siV7
siEx1
siEx7
ARv7
AR-NT
β-actin
100 kd
75 kd
D
PC2, 24.6% variation
PC1, 33.61% variation
siNTC_3
siNTC_1
siNTC_2
siEx7_3
siEx7_2
siEx7_1
siV7_3
siV7_1
siV7_2
siEx1_3
siEx1_2
siEx1_1
ARCC-32_2
DMSO_1
ARCC-32_1
DMSO_3
ARCC-32_3
DMSO_2
B
VCaP16 siV7 vs siNTC
HALLMARK_ANDROGEN_RESPONSE
Enrichment score (ES)
FDR: 0
NES: -2.2596
Positive
VCaP16 siV7 vs siNTC
Negative
Ranking metric
Rank in ordered gene list
C
VCaP16 siEx7 vs siNTC
HALLMARK_ANDROGEN_RESPONSE
FDR: 0.7387
NES: -0.8830
Positive
VCaP16 siEx7 vs siNTC
Negative
Rank in ordered gene list
E
VCaP16
DMSO
ARCC-32
AR-NT
ERG
PSA
Vinculin
100 kd
75 kd
F
VCaP16 ARCC-32 vs DMSO
HALLMARK_ANDROGEN_RESPONSE
FDR: 0.8931
NES: 0.9809
Positive
VCaP16 ARCC-32 vs DMSO
Negative
Rank in ordered gene list
G
VCaP16 -vs- VCaP
-log10(P Value)
log2FC
VCaP16 (siV7) -vs- VCaP16 (siNTC)
H
VCaP16
siNTC + ENZ
siNTC + ENZ + ARCC-32
siV7 + ENZ
siV7 + ENZ + ARCC-32
Live Cell OD (485nm/535nm)
Day
****
**

951 **Figure 2. AR activity in VCaP16 cells is dependent on ARv7. A)** *Upper, KLK3* gene expression by qRT-PCR
952 and *Lower*, immunoblot for ARfl and ARv7 in VCaP16 cells after siRNA knockdown with non-targeting control
953 (siNTC), ARv7 (siV7), both ARv7 and ARfl (siEx1), or just Arfl (siEx7) siRNA. **B, C)** Enrichment for Hallmark
954 Androgen Response gene set in RNA isolated from VCaP16 cells with siRNA knockdown of ARv7 (siV7) or ARfl
955 (siEx7). Significantly differentially expressed genes (adjusted p-value < 0.05) were used as an input. **D)** Principal
956 component analysis of RNA-seq data from VCaP16 cells with siRNA knockdown described in *A),* with addition
957 of VCaP16 cells in DMSO (DMSO) and VCaP16 cells treated with ARCC-32 (500 nM) for 36 hrs. **E)** Immunoblot
958 of protein from VCaP16 in DMSO and VCaP16 cells treated with ARCC-32 (500 nM) for 36 hrs. **F)** Enrichment
959 for Hallmark Androgen Response gene set in RNA-seq data from VCaP16 cells in DMSO and VCaP16 cells
960 treated with ARCC-32 (500 nM) for 36 hrs. All differentially expressed genes were used as an input. **G)**
961 **Differential** gene expression of the 59 genes that make up the ARv7 gene set from Sharp et al. comparing
962 VCaP16 versus VCaP cells (left) or VCaP16 treated with ARv7 siRNA versus non-target control siRNA (siNTC)
963 (right). **H)** Live cell DNA fluorescence in VCaP16 cells treated with non-target control siRNA (siNTC) or ARv7
964 siRNA (siV7) +/- 500 nM ARCC-32.

965

Figure 3


A
Days Enz
DMSO
2
4
7
14
21
28
VCaP16
VCaP16
AR-NT LE
AR-NT SE
ARv7
PSA
β-actin
100 kd
75 kd
B
VCaP
VCaP-E
VCaP16
DAPI
ARv7
CBP
ARv7 CBP
Merge
C
ARv7 Puncta/Nuclei
VCaP-D
VCaP-E
VCaP16
D
CBP/P300 %ARv7 co-localization
VCaP-E
VCaP16
E
VCaP
VCaP16
ENZ
DHT
AR-NT
ARv7
GAPDH
100 kd
75 kd
F
ARv7 binding sites
Number of binding sites
VCaP
VCaP16
ARv7 VCaP16 ENZ -1
N = 2150
ARv7 VCaP16 ENZ -2
ENZ
DHT
G
ARfl binding sites
Number of binding sites
VCaP
VCaP16
ENZ
DHT

966 **Figure 3. ARv7 induced acutely by ENZ is nuclear but lacks chromatin binding capacity. A)** Immunoblot
967 of protein isolated from VCaP cells treated with 16 μM ENZ from 2-28 days and protein isolated from VCaP16
968 cells. AR-NT, antibody targeting AR N-terminus (long and short exposures). **B)** Confocal immunofluorescence
969 imaging of ARv7 and CBP/p300 in DMSO or 16 μM ENZ (4 days) treated VCaP cells versus VCaP16 cells
970 (maintained in 16 μM ENZ). **C, D)** Quantification of z-stack 3-dimensional images produced from panel showing
971 number of ARv7 puncta per nuclei in four fields (C) and fraction of ARv7 puncta that also contain CBP/p300 (D).
972 **E)** Immunoblot of chromatin fraction isolated from VCaP and VCaP16 cells following formalin crosslinking for
973 ChIP. VCaP cells were grown in 10% FBS supplemented with 16 μM ENZ for 72 hrs and media was then replaced
974 with fresh 10% FBS medium supplemented with 16 μM ENZ or 10 nM DHT for 4 hrs prior to crosslinking**.** VCaP16
975 cells were in maintenance media (10% FBS, 16μM ENZ) and then media was replaced with fresh 10% FBS
976 medium supplemented with 16 μM ENZ or 10 nM DHT for 4 hrs prior to crosslinking. **F)** ARv7 binding sites based
977 on ChIP-seq in samples from (E) and Venn diagram showing overlap between ARv7 sites in VCaP16 cells (ENZ)
978 in biological replicates. **G)** ARfl binding sites as seen by AR C-terminal antibody ChIP-seq on samples in (E).

979

Figure 4


A
Cytoplasm
Soluble nucleus
Chromatin bound
NC
ARD 48h
ARD 24h
AR-N
AR-V7
HOXB13
HDAC2
HSP90
H3
1/10 dilution


B
VCaP16
DMSO
ARCC-32
0.75
0.50
0.25
ARv7 binding sites, N = 2,682
0.8
0.6
0.4
0.2
AR
-/+ 2Kb


C
Number of binding sites
8000
6000
4000
2000
0
ns
DMSO
ARCC-32


D
ARCC-32
ARv7 = 4,834
2,682
DMSO
ARv7 = 798


E
IP
Input
IgG
AR-V7
AR-C
HOXB13
AR degrader
-
+
AR-N
HOXB13
BGR1
IgG


F
ARfl
80,117
10,931
ARv7
193


G
VCaP16
ARv7
ARfl
ENZ
DHT
ENZ
DHT
10
0
ARv7 binding sites, N = 11,124
AR
-/+ 2Kb
0.0
0.5
1.0
1.5
0
4
8
12


H
LNCaP95
DMSO
DHT
DEX
2
0
ARv7 binding sites, N = 2,150
1.75
1.50
1.25
1.00
0.75
0.50
0.25
0.00
AR
-/+ 2Kb

980 **Figure 4. ARv7 chromatin binding in VCaP16 cells is independent of ARfl. A)** VCaP16 cells in basal medium
981 (16 μM ENZ) were treated for 24 or 48 hrs with vehicle (NC) or ARCC-32 (500 nM). Cells were then separated
982 into cytoplasmic, soluble nuclear, or chromatin fractions and immunoblotted as indicated. **B)** Heatmap showing
983 the intensity of ARv7 binding in VCaP16 cells in their basal medium (with 16 μM ENZ) with addition of DMSO or
984 ARCC-32 (500 nM) for 36 hrs. ChIP-seq signal is centered at ARv7 sites common between both conditions. **C)**
985 Number of ARv7 binding sites in VCaP16 cells in basal medium (with 16 μM ENZ) treated with DMSO or ARCC-
986 32 (500 nM) for 36 hrs. **D)** Venn diagram showing the intersection of merged ARv7 sites in VCaP16 cells in
987 DMSO (DMSO) or ARCC-32 (500 nM). **E**) VCaP16 cells were double crosslinked with DSP and formaldehyde.
988 The chromatin fraction was then isolated and solubilized by DNA digestion with benzonase, followed
989 immunoprecipitation with ARv7, AR C-terminal (ARfl), or HOXB13 antibodies and immunoblotting as indicated.
990 **F)** Venn diagram showing the intersection of ARv7 and ARfl sites in VCaP16 cells following 4 hr treatment with
991 DHT (10 nM). **G)** Heatmap showing increased binding intensity of ARv7 and ARfl in VCaP16 cells following 4 hr
992 treatment with DHT (10 nM). ChIP-seq signal is centered at ARv7 sites identified in VCaP16 cells following 4 hr
993 treatment with DHT (10 nM). **H)** Heatmap showing the enrichment of ARv7 binding in LNCaP95 cells in basal
994 medium treated for 2 hrs with DMSO, DHT (10 nM) (DHT), or dexamethasone (DEX, 100 nM). ChIP-seq signal
995 is centered at ARv7 sites identified in VCaP16 cells.

996

Figure 5


A
ARfl
52,536
ARv7
66
2,084
B
VCaP16
ARfl
ARv7
Input
ARv7
N = 2,084
ARfl binding sites, N = 52,536
AR
-/+ 2Kb
C
VCaP16
VCaP-E
ARfl
ARv7
ARv7
ARfl binding sites, N = 54,620
D
ARfl
ARv7
Input
ARv7
ARfl
-2.0
AR
2.0Kb
E
VCaP16
VCaP
ENZ
DHT
DHT
ENZ
ARfl binding sites, N = 91,048
F
R = 0.57, p < 2.2e-16
VCaP16
ARfl unique
R = 0.85, p < 2.2e-16
VCaP16
ARv7/ARfl
Normalized count ARfl
Normalized count ARv7
G
R = 0.66, p < 2.2e-16
VCaP16 DHT
ARfl unique
R = 0.88, p < 2.2e-16
VCaP16 DHT
ARv7/ARfl
H
ARN20
ARfl
ARv7
ARv7
N = 2,084
ARfl binding sites, N = 52,536
GSM2842708
GSM2842700
GSM2842704
I
R = 0.55, p < 2.2e-16
LNCaP95
ARfl unique
R = 0.84, p < 2.2e-16
LNCaP95
ARv7/ARfl
Motif enrichment (+/-100 bp)
ARv7/ARfl
ARfl unique
FOXA1
FOXM1
Foxa2
FOXA1
THRb
AR-halfsite
GRE
PGR
GRE
ARE
PR
% of targets with motif

997 **Figure 5. ARv7 binding sites overlap with ARfl binding sites with proportionate peak intensities. A)** Venn
998 diagram showing the intersection of ARv7 and ARfl sites in VCaP16 cells in basal medium (with 16 μM ENZ). **B)**
999 Heatmap showing correlation between ARfl and ARv7 binding at called ARv7 sites (upper) and at ARfl unique
1000 sites. **C)** Heatmap showing correlation between ARv7 and ARfl binding intensities across all ARfl sites in
1001 VCaP16, and showing ARv7 in VCaP after short term ENZ treatment (4 days) (VCaP-E). **D)** Profile plots showing
1002 peak intensities for ARfl and ARv7 in VCaP16 cells at ARv7 versus ARfl unique binding sites. ChIP-seq signal
1003 is centered at ARv7/ARfl shared (ARv7) and ARfl unique (ARfl) sites identified in VCaP16. Input sample does
1004 not show signal enrichment at centered genomic regions. **E)** ARfl binding intensities in 1) VCaP16 maintained in
1005 basal medium with 16 μM ENZ, 2) VCaP16 treated with DHT (10 nM) for 4hrs, 3) VCaP cells treated with ENZ
1006 for 72 hrs followed by removal of ENZ and addition of DHT (10 nM) for 4 hrs, and 4) VCaP cells treated with ENZ
1007 for 72 hrs. ChIP-seq signal is centered at total ARfl sites identified in VCaP16 cells stimulated with DHT (10 nM)
1008 for 4hrs. **F)** Pearson's correlation of normalized read counts: ARv7 versus ARfl called at shared ARfl/ARv7 and
1009 ARfl unique sites in VCaP16 cells and **G)** in VCaP16 cells treated with DHT (10 nM) for 4hrs. **H)** Heatmap
1010 showing the AR signal enrichment with AR N-terminal (GSM2842708), AR C-terminal (GSM2842700), and ARv7
1011 (GSM2842704) antibodies in LNCaP95 cells. ChIP-seq signal is centered at shared ARfl/ARv7 (ARv7) sites and
1012 ARfl unique sites identified in VCaP16 cells**. I)** Pearson's correlation of normalized read counts: ARv7
1013 (GSM2842704) versus ARfl (GSM2842700) in LNCaP95 cells at shared ARfl/ARv7 (ARv7) sites and ARfl unique
1014 sites identified in VCaP16 cells. **J)** Top enriched motifs (+/-100 kb from the peak center) at ARfl unique sites and
1015 at shared ARfl/ARv7 sites in VCaP16 cells.

1016

Figure 6


A
VCaP16 siV7 vs VCaP-E
Pearson r2 = 0.7553
p-value < 0.0001
r = 0.8691
VCaP-E log2(Fold-Change)
VCaP16 siV7 log2(Fold-Change)
B
VCaP16 siV7 vs siEx7
Pearson r2 = 0.3092
p-value < 0.0001
r = 0.5561
VCaP16 siEx7 log2(Fold-Change)
VCaP16 siV7 log2(Fold-Change)
C
VCaP16 siV7 vs ARCC-32
Pearson r2 = 0.2950
p-value < 0.0001
r = -0.5431
VCaP16 ARCC-32 log2(Fold-Change)
VCaP16 siV7 log2(Fold-Change)
D
VCaP16 siEx1 vs siEx7
Pearson r2 = 0.5990
p-value < 0.0001
r = 0.7739
VCaP16 siEx7 log2(Fold-Change)
VCaP16 siEx1 log2(Fold-Change)
E
VCaP16 siEx1 vs siV7
Pearson r2 = 0.8866
p-value < 0.0001
r = 0.9416
VCaP16 siV7 log2(Fold-Change)
VCaP16 siEx1 log2(Fold-Change)
F
ARv7/ARfl co-bound sites
(+/- 5kb from TSS)
***
*
****
log2(Fold-Change)
siEx1
siEx7
siV7
ARCC-32
G
VCaP16 gene expression altered by siV7
(ARv7/ARfl sites, siV7 RNA-seq)
KLK3
KLK2
HOMER2
PMEPA1
FKBP5
FASN
ACADBCL6
CYP51A1
INPP4B
ETF1
NAMPT
– Log10 P
NS
Log2 FC
p-value
p – value and log2 FC
H
1 2 3 4 5 6 7 8 9 10
BCL6
ACADL
ELOVL6
CSF1
CEBPD
CXCL1
PER1
NAMPT
PSMC2
DHCR24
PSAT1
DDIT4
ATP6V0D1
KLK2
ADAMTS1
KLK3
NDRG1
SPDEF
TMPRSS2
PMEPA1
DNAJB9
FKBP5
ABHD2
HOMER2
TOB1
GAL
LAMC1
KCNMA1
SIPA1L1
INPP4B
TSKU
FASN
GNAI1
CYP51A1
WEE1
PEA15
ETF1
PMAIP1
MSigDB Hallmark 2020
1. Androgen Response
2. mTORC1 Signaling
3. mTNF-alpha Signaling via NF-kBTORC1 Signaling
4. Estrogen Response Early
5. Unfolded Protein Response
6. Adipogenesis
7. Estrogen Response Late
8. Cholesterol Homeostasis
9. UV Response Dn
10. Apoptosis
-log10(padj)
Androgen Response
mTORC1 Signaling
-log10(padj)
Odds Ratio

1017 **Figure 6. ARv7 transcriptome in VCaP16 is highly correlated with ARfl in VCaP. A)** Correlation of log2(Fold-
1018 Change) values of significantly differentially expressed genes (padj < 0.05) in RNA-seq data from (x-axis)
1019 VCaP16 with siRNA knockdown of ARv7 versus non-targeting control (VCaP16 siV7) and (y-axis) VCaP cells
1020 treated with ENZ for 4 days versus parental VCaP cells (VCaP-E). **B)** Correlation of (x-axis) VCaP16 with siRNA
1021 knockdown of ARv7 versus non-targeting control (VCaP siV7) and (y-axis) VCaP16 with siRNA knockdown of
1022 Exon7 (targets ARfl) versus non-targeting control (VCaP siEx7). **C)** Correlation of (x-axis) VCaP16 with siRNA
1023 knockdown of ARv7 versus non-targeting control (VCaP16 siV7) and (y-axis) VCaP16 treated with ARCC-32
1024 (500 nM) versus VCaP16 in DMSO (VCaP16 ARCC-32). **D)** Correlation of (x-axis) VCaP16 with siRNA
1025 knockdown of Exon1 (targets ARfl and ARv7) versus non-targeting control (VCaP siEx1) and (y-axis) VCaP16
1026 with siRNA knockdown of Exon7 (targets ARfl) versus non-targeting control (VCaP siEx7). **E)** Correlation of (x-
1027 axis) VCaP16 with siRNA knockdown of Exon1 (targets ARfl and ARv7) versus non-targeting control (VCaP
1028 siEx1) and (y-axis) VCaP16 with siRNA knockdown of ARv7 versus non-targeting control (VCaP16 siV7). **F)**
1029 Differential expression (log2(Fold-Change) values) of ARv7-regulated genes (where ARv7 binding sites are
1030 located within +/- 5 kb from TSS) altered by siV7, siEx1, siEx7 or ARCC-32 in RNA-seq from VCaP16 cells.
1031 Differentially expressed genes with padj < 0.05 (siV7, siEx1, siEx7) and p-value < 0.05 (ARCC-32) were included.
1032 Mann-Whitney U, two-tailed: siV7 vs siEx7, p-value = 0.0308; siV7 vs siEx1, p-value = 0.8151; siV7 vs ARCC-
1033 32, p-value < 0.0001; siEx1 vs siEx7, p-value = 0.0609; ARCC-32 vs siEx7, p-value = 0.1148; ARCC-32 vs Ex1,
1034 p-value = 0.0005. **G)** Volcano plot of differentially expressed genes linked to ARv7 binding sites in VCaP16 cells
1035 (+/- 100 kb from TSS) in RNA-seq data from VCaP16 with siRNA knockdown of ARv7 (siV7) versus non-targeting
1036 control. **H)** Enrichment analysis by Enrichr of downregulated genes from G.

1037

Figure 7


A
ATAC
VCaP
VCaP-ENZ
VCaP16
-2.0
ATAC
2.0Kb
B
Number of peaks
VCaP
VCaP-E
VCaP16
C
VCaP
VCaP-E
VCaP16
UP
N = 9,829
Unchanged
N = 70,269
Down
N = 645
ATAC
-/+2Kb
D
UP
Unchanged
Down
E
ARv7/ARfl
1,239
ATAC-UP
8,984
845
40.5%
ATAC-UP
4,456
ARfl
52,536
5,373
10.2%
F
ATAC-seq at ARv7/ARfl
ATAC-seq at ARfl unique
AR
G
MNase-seq at ARv7/ARfl
MNase-seq at ARfl unique
ARv7
ARfl
0.5Kb

1038 **Figure 7. Chromatin accessibility in VCaP16 cells is increased at ARv7 binding sites. A)** Profile plot
1039 showing ATAC-seq signal in parental VCaP cells, VCaP cells treated with ENZ for 4 days (VCaP-E) and VCaP16
1040 (centered on all sites). **B)** ATAC-seq sites in parental VCaP cells, VCaP cells treated with ENZ for 4 days (VCaP-
1041 E) and VCaP16. **C)** Heatmap and **D)** profile plots showing the ATAC-seq signal strength in parental VCaP cells,
1042 VCaP cells treated with ENZ for 4 days (VCaP-E) and VCaP16. ATAC-seq signal is centered at sites with
1043 increased ATAC signal (UP sites), sites called as unchanged (Unchanged sites), or sites with decreased ATAC
1044 signal (Down sites) in VCaP16 versus parental VCaP cells as identified with CoBRA pipeline. **E)** Overlap of
1045 differentially more accessible sites (ATAC-UP) with shared ARv7/ARfl (upper panel) and ARfl unique binding
1046 sites (lower panel) in VCaP16 cells. **F)** Profile plots showing ATAC-seq signal enrichment and **G)** nucleosome
1047 occupancy by MNase-seq at ARv7/ARfl (upper panels) and ARfl unique binding sites (lower panels) in VCaP16
1048 cells.

1049

Figure 8


A
Motif Enrichment: ATAC-UP sites
-(LogP-value)
Rank
ARE
NFI
NFI-halfsite
FOXA1
AR-halfsite
GRHL2
FOXA1
HOXB13
TRPS1
Homeobox
NR
CP2
CTF
Other
Zf
ETS
Forkhead
B
NFI motif enricment at ATAC sites
Proportion
****
****
UP
Unchanged
Down
C
Fragment length
Distance to binding site
D
VCaP-E
VCaP16
ARE motif enrichment
Proportion
ARfl/ARv7
ARfl unique
E
FOXA1 motif enrichment
F
HOXB13 motif enrichment
G
NFI motif enrichment
H
NFI motif enricment at ARfl bs
AREs
other
I
R = 0.62, p < 2.2e-16
log2(Fold-Change) siNFIB/X
log2(Fold-Change) siV7
J
R = 0.28, p < 2.2e-16
log2(Fold-Change) siFOXA1
K
NFI motif enrichment
GSE130408
GSE137527
N
PC

Figure 8. ARv7 activity in VCaP16 is dependent on Nuclear Factor I transcription factors. A) Motif enrichment analysis by HOMER at differentially more accessible sites (ATAC-UP) in VCaP16 cells. **B)** NFI motif enrichment by HOMER at ATAC-seq differentially more accessible sites (UP), unchanged (Unchanged) or differentially closed sites (Down) in VCaP16 versus parental VCaP cells as identified with CoBRA pipeline (****p<0.0001, Fisher Exact Test). **C)** Vplot showing NFI motif footprint at differentially more accessible sites (ATAC-UP) in VCaP16 cells. **D)** Enrichment for the ARE, **E)** HOXB13, **F)** FOXA1 and **G)** NFI motifs by HOMER at ARv7/ARfl shared and ARfl unique sites in VCaP cells after short term ENZ treatment (VCaP-E) versus in VCaP16 cells. **H)** NFI motif enrichment by HOMER at AR binding sites with canonical full AREs versus those with non-consensus AREs (others) in VCaP cells after short term ENZ treatment (VCaP-E) versus in VCaP16 cells. **I)** Pearson's correlation of log2(Fold-Change) values of significantly differentially expressed genes (padj < 0.1) altered with siRNA knockdown of ARv7 (siV7) versus siRNA knockdown of NFIB and NFIX (siNFIB/X) and **J)** versus siRNA knockdown of FOXA1 (siFOXA1) in VCaP16 cells. **K)** NFI motif enrichment by HOMER at AR binding sites in normal prostate tissue (N) versus primary prostate cancer (PC) in two clinical datasets, GSE139498 and GSE137527 (*p<0.05, **p<0.01, Mann-Whitney test).